The influence of drug-like concepts on decision-making in medicinal chemistry

DOI: 10.1038/nrd2445
Nature Reviews Drug Discovery, 2007, 6, 881-90.

#	Paper	IF	Citations
1830	Lipophilic Metabolic Efficiency (LipMetE) and Drug Efficiency Indices to Explore the Metabolic Properties of the Substrates of Selected Cytochrome P450 Isoforms.		
1829	Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. **2008**, 3, 1905-12		34
1828	[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. **2008**, 18, 1795-8		12
1827	Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. **2008**, 18, 2562-6		26
1826	Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity. **2008**, 18, 2896-9		28
1825	IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. **2008**, 18, 3656-60		45
1824	N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors. **2008**, 18, 4308-11		12
1823	Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. **2008**, 18, 6033-6		12
1822	The impact of natural products upon modern drug discovery. **2008**, 12, 306-17		421
1821	Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. **2008**, 18, 4355-9		12
1820	Design and optimization of potent, selective antagonists of Oxytocin. **2008**, 18, 4278-81		10
1819	Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. **2008**, 364, 298-327		586
1818	Lead finder: an approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual screening. **2008**, 48, 2371-85		140
1817	Virtual screening of the estrogen receptor. **2008**, 3, 853-66		3
1816	Applications of physiologically based absorption models in drug discovery and development. **2008**, 5, 760-75		94
1815	Network pharmacology: the next paradigm in drug discovery. **2008**, 4, 682-90		2255
1814	Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. *Nature Reviews Drug Discovery*, **2008**, 7, 205-20	64.1	360

1813	Assessing drug-likeness--what are we missing?. **2008**, 13, 285-94	198
1812	Limitations and lessons in the use of X-ray structural information in drug design. **2008**, 13, 831-41	133
1811	Safety and secondary pharmacology: successes, threats, challenges and opportunities. **2008**, 58, 77-87	82
1810	In Silico Prediction of Solubility. **2008**, 53-68	2
1809	Impact of Chemistry Information on Pathway Analysis. **2008**, 219-236	
1808	The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. **2008**, 384, 1002-17	251
1807	Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki coupling. **2008**, 10, 3259-62	67
1806	Lipid bilayer-mediated regulation of ion channel function by amphiphilic drugs. **2008**, 131, 421-9	77
1805	Pharmacological Space. **2008**, 521-532	2
1804	Pharmacological Space. **2008**, 395-408	
1803	Lead generation: reality check on commonly held views. **2008**, 3, 733-44	7
1802	In Silico Prediction of Human Bioavailability. **2008**, 433-451	2
1801	Physicochemical Approaches to Drug Absorption. **2008**, 69-99	3
1800	Drug Discoveries by Gene Family. **2008**, 1-13	
1799	Ion Channels. **2009**,	
1798	The use of computer models in pharmaceutical safety evaluation. **2009**, 37, 467-75	14
1797	Cell based in vitro and ex vivo models in metabolic disease drug discovery: nice to have or critical path?. **2009**, 4, 417-28	0
1796	Modulation of the partition coefficient between octanol and buffer at pH 7.4 and pKa to achieve the optimum balance of blood clearance and volume of distribution for a series of tetrahydropyran histamine type 3 receptor antagonists. **2009**, 37, 1864-70	37

1795	Endothelin receptor antagonists: status and learning 20 years on. **2009**, 47, 203-37	17
1794	The rise of the intelligent machines in drug hunting?. **2009**, 1, 405-8	6
1793	4th Anglo-Swedish Medicinal Chemistry Symposium. **2009**, 1, 431-4	2
1792	From fragment screening to potent binders: strategies for fragment-to-lead evolution. **2009**, 9, 956-61	12
1791	Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database. **2009**, 37, 2204-11	12
1790	Two 'Golden Ratio' indices in fragment-based drug discovery. **2009**, 14, 321-8	49
1789	'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. **2009**, 14, 31-40	103
1788	Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality. **2009**, 14, 598-604	51
1787	From fragment to clinical candidate--a historical perspective. **2009**, 14, 668-75	186
1786	The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?. **2009**, 14, 1011-20	512
1785	HTS and hit finding in academia--from chemical genomics to drug discovery. **2009**, 14, 1150-8	66
1784	The chemist as astronaut: searching for biologically useful space in the chemical universe. **2009**, 78, 217-23	36
1783	A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein. **2009**, 36, 254-64	29
1782	Application of a Dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates. **2009**, 37, 172-82	44
1781	Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. **2009**, 4, 680-6	129
1780	A practical method for targeted library design balancing lead-like properties with diversity. **2009**, 4, 800-8	24
1779	A practical total synthesis of the microbial alkaline proteinase inhibitor (MAPI). **2009**, 4, 2054-9	
1778	Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors. **2009**, 4, 1985-9	58

1777	Accelerating botulism therapeutic product development in the Department of Defense. **2009**, 70, 303-326		4
1776	Similarity methods in chemoinformatics. **2009**, 43, 1-117		51
1775	Improving compound quality through in vitro and in silico physicochemical profiling. **2009**, 6, 1760-6		33
1774	Recent advances in physicochemical and ADMET profiling in drug discovery. **2009**, 6, 1887-99		36
1773	Structural pairwise comparisons of HLM stability of phenyl derivatives: Introduction of the Pfizer metabolism index (PMI) and metabolism-lipophilicity efficiency (MLE). **2009**, 23, 97-103		49
1772	The multiple roles of computational chemistry in fragment-based drug design. **2009**, 23, 459-73		44
1771	Fragment-based drug discovery. **2009**, 23, 453-8		35
1770	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. **2009**, 2, 2		349
1769	The rise of fragment-based drug discovery. **2009**, 1, 187-92		503
1768	A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. **2009**, 15, 750-6		320
1767	The influence of lead discovery strategies on the properties of drug candidates. *Nature Reviews Drug Discovery*, **2009**, 8, 203-12	64.1	466
1766	Targeting protein kinases in central nervous system disorders. *Nature Reviews Drug Discovery*, **2009**, 8, 892-909	64.1	201
1765	Medicinal chemistry: Exploring the third dimension. *Nature Reviews Drug Discovery*, **2009**, 8, 931	64.1	24
1764	Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. **2009**, 74, 457-67		132
1763	New quinoline NK3 receptor antagonists with CNS activity. **2009**, 19, 837-40		36
1762	Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase. **2009**, 19, 665-9		18
1761	Antinociceptive properties of caffeic acid derivatives in mice. **2009**, 44, 4596-602		38
1760	ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. **2009**, 17, 5906-19		93

1759	Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity. **2009**, 19, 481-4	35
1758	Synthesis and evaluation of 2-pyridyl pyrimidines with in vitro antiplasmodial and antileishmanial activity. **2009**, 19, 401-5	37
1757	2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology. **2009**, 19, 1702-6	10
1756	4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships. **2009**, 19, 2829-34	12
1755	Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. **2009**, 19, 2844-51	227
1754	Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. **2009**, 19, 4406-9	220
1753	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. **2009**, 19, 4579-83	2
1752	Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists. **2009**, 19, 5346-50	7
1751	Pyrazole NNRTIs 3: optimisation of physicochemical properties. **2009**, 19, 5603-6	20
1750	Using the Golden Triangle to optimize clearance and oral absorption. **2009**, 19, 5560-4	192
1749	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. **2009**, 19, 5857-60	82
1748	Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist. **2009**, 19, 6144-7	13
1747	Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds. **2009**, 19, 6943-7	31
1746	Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. **2009**, 11, 45-53	117
1745	Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. **2009**, 131, 4490-8	205
1744	Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. **2009**, 52, 379-88	267
1743	Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5. **2009**, 52, 3063-72	10
1742	Chapter 4 Case History: Chantix/Champix (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid. **2009**, 71-101	14

1741	Physicochemical drug properties associated with in vivo toxicological outcomes: a review. **2009**, 5, 921-31	118
1740	Do biologically relevant compounds have more chance to be drugs?. **2009**, 49, 2376-81	17
1739	Chapter 6 Advances in Vasopressin Receptor Agonists and Antagonists. **2009**, 44, 129-147	10
1738	Discovery DMPK: changing paradigms in the eighties, nineties and noughties. **2009**, 4, 207-18	21
1737	Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. **2009**, 48, 1-29	32
1736	In Silico Tools and In Vitro HTS Approaches to Determine Lipophilicity During the Drug Discovery Process. **2009**, 91-116	
1735	In Vitro Safety Pharmacology Profiling: An Important Tool to Decrease Attrition. **2009**, 273-295	2
1734	Overview of Hit to Lead: The Medicinal Chemist's Role from HTS Retest to Lead Optimization Hand Off. **2009**, 1-24	3
1733	Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?. **2009**, 49, 1025-32	49
1732	Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. **2009**, 5, 1536-48	82
1731	Chemogenomics. **2009**,	3
1730	Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites. **2009**, 52, 7706-23	26
1729	Advances in fragment-based drug discovery platforms. **2009**, 4, 1125-44	25
1728	Introduction to computational oral absorption simulation. **2009**, 5, 259-93	95
1727	Solid-phase synthesis of biologically active benzoannelated nitrogen heterocycles: an update. **2009**, 11, 175-97	125
1726	Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. **2009**, 52, 234-7	58
1725	[Pharmaceutical research in the early stages of drug discovery--significance and practice]. **2009**, 133, 149-53	
1724	Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics. **2009**, 9, 1688-704	6

1723	Implications of the dominant role of transporters in drug uptake by cells. **2009**, 9, 163-81	76
1722	Advances in the integration of drug metabolism into the lead optimization paradigm. **2009**, 9, 703-16	25
1721	Use of Biological Fingerprints Versus Structure/Chemotypes to Describe Molecules. **2010**, 481-504	1
1720	Receptor Targets in Drug Discovery. **2010**, 499-548	
1719	[Fragment-based drug discovery: concept and aim]. **2010**, 130, 315-23	3
1718	Fragment-Based Drug Design: Considerations for Good ADME Properties. **2010**, 417-485	
1717	Gramicidin-based fluorescence assay; for determining small molecules potential for modifying lipid bilayer properties. **2010**,	24
1716	Some Trends in Chem(o)informatics. **2011**, 672, 1-37	15
1715	Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. **2010**, 1, 435-49	610
1714	Integration of small-molecule discovery in academic biomedical research. **2010**, 77, 350-7	19
1713	Lipophilicity in drug discovery. **2010**, 5, 235-48	526
1712	Selectively nonselective kinase inhibition: striking the right balance. **2010**, 53, 1413-37	247
1711	Chapter 1:Drugs and their Structural Motifs. **2010**, 1-60	3
1710	Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. **2010**, 84, 825-89	292
1709	Characteristics of known drug space. Natural products, their derivatives and synthetic drugs. **2010**, 45, 5646-52	67
1708	Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies. **2010**, 18, 1421-7	26
1707	Using protein-ligand docking to assess the chemical tractability of inhibiting a protein target. **2010**, 16, 1833-43	12
1706	Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. **2010**, 15, 648-55	174

1705	Thermodynamics guided lead discovery and optimization. **2010**, 15, 919-32	111
1704	Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs. **2010**, 5, 187-90	22
1703	Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates. **2010**, 5, 2102-13	29
1702	Drug efficiency indices for improvement of molecular docking scoring functions. **2010**, 31, 174-84	46
1701	Iridium-Catalyzed Asymmetric Allylic Amination with Polar Amines: Access to Building Blocks with Lead-Like Molecular Properties. **2010**, 352, 3153-3157	30
1700	Lead Discovery: The Process. **2010**, 1-19	
1699	High Throughput Screening Approach to Lead Discovery. **2010**, 21-71	4
1698	Fragment-Based Lead Discovery. **2010**, 105-139	3
1697	Role of Chemistry in Lead Discovery. **2010**, 259-290	3
1696	Challenges in the Synthesis of Natural and Non-Natural Volatiles. **2010**, 173-202	8
1695	Faktoren f□ die Auswahl organischer Reaktionen in der medizinischen Chemie und die Anwendung dieser Reaktionen in Arrays (kleinen fokussierten Bibliotheken). **2010**, 122, 8258-8267	48
1694	Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries). **2010**, 49, 8082-91	208
1693	Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. **2010**, 20, 1084-9	22
1692	Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization. **2010**, 20, 196-200	20
1691	Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. **2010**, 20, 632-5	28
1690	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists. **2010**, 20, 1114-7	6
1689	Spirocyclic ureas: orally bioavailable 11 beta-HSD1 inhibitors identified by computer-aided drug design. **2010**, 20, 881-6	21
1688	Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists. **2010**, 20, 1752-7	12

1687	Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres. **2010**, 20, 2229-33	16
1686	Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. **2010**, 20, 2770-5	14
1685	Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. **2010**, 20, 3161-4	18
1684	Optimisation of a pyrazole series of progesterone antagonists; Part 1. **2010**, 20, 3384-6	4
1683	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. **2010**, 20, 3788-92	4
1682	Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptor. **2010**, 20, 4653-6	19
1681	Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. **2010**, 20, 5308-12	53
1680	Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. **2010**, 20, 5080-4	44
1679	Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG. **2010**, 20, 6237-41	6
1678	Discovery and optimization of adamantyl carbamate inhibitors of 11╫HSD1. **2010**, 20, 6725-9	12
1677	Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution. **2010**, 20, 6483-8	60
1676	Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor. **2010**, 20, 6370-4	20
1675	Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. **2010**, 20, 6969-74	33
1674	The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. **2010**, 159, 49-57	104
1673	Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines. **2010**, 159, 25-33	26
1672	Challenges of antibacterial discovery revisited. **2010**, 1213, 5-19	138
1671	Integrated approaches to lead optimization: improving the therapeutic index. 183-203	
1670	Predictive toxicology approaches for small molecule oncology drugs. 204-229	

1669	NMR in fragment-based drug discovery. 41-58	2
1668	Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. **2010**, 5, 609-18	39
1667	Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. **2010**, 335, 636-44	102
1666	Amphiphile regulation of ion channel function by changes in the bilayer spring constant. **2010**, 107, 15427-30	93
1665	Predictive toxicology approaches for small molecule oncology drugs. **2010**, 38, 148-64	14
1664	Towards a more robust approach to selecting and prosecuting promising targets and compounds. **2010**, 2, 25-34	1
1663	Screening for small molecules' bilayer-modifying potential using a gramicidin-based fluorescence assay. **2010**, 8, 427-36	54
1662	Mitigating permeability-mediated risks in drug discovery. **2010**, 6, 171-87	11
1661	Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. **2010**, 13, 207-18	19
1660	Binding Mode Prediction of PDE4 Inhibitors: A Comparison of Modelling Methods. **2010**, 63, 396	3
1659	Conference report: trekking through receptor chemistry. **2010**, 2, 1247-52	
1658	Biomolecular Structure and Modeling: Historical Perspective. **2010**, 1-40	
1657	Molecular Dynamics: Further Topics. **2010**, 463-517	0
1656	Design of selective, ATP-competitive inhibitors of Akt. **2010**, 53, 4615-22	52
1655	Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks. **2010**, 380-391	59
1654	Drug Discovery and Early Drug Development. **2010**, 1-24	
1653	Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans. **2010**, 53, 3183-97	29
1652	Kinase Inhibitors: Approved Drugs and Clinical Candidates. **2010**, 295-344	3

1651	Direct renin inhibitors as a new therapy for hypertension. **2010**, 53, 7490-520	63
1650	Ligand efficiency as a guide in fragment hit selection and optimization. **2010**, 7, e147-202	121
1649	The heat is on: thermodynamic analysis in fragment-based drug discovery. **2010**, 7, e147-202	16
1648	In Silico ADME/Tox Predictions. **2010**, 29-124	4
1647	Hepatic Toxicity. **2010**, 353-377	
1646	Cheminformatic tools for medicinal chemists. **2010**, 53, 4830-41	63
1645	Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. **2010**, 53, 7902-17	986
1644	Predicting oral druglikeness by iterative stochastic elimination. **2010**, 50, 437-45	25
1643	Identification and characterization of acidic mammalian chitinase inhibitors. **2010**, 53, 6122-8	32
1642	Compound Collection Enhancement and Paradigms for High-Throughput Screening an Update. **2010**, 45, 409-428	12
1641	Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties. **2010**, 53, 3927-36	106
1640	Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. **2010**, 1, 420-34	313
1639	Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. **2010**, 1, 139	64
1638	Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus. **2010**, 2, 1181-203	24
1637	Oxetanes in drug discovery: structural and synthetic insights. **2010**, 53, 3227-46	280
1636	Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. **2010**, 197, 175-82	44
1635	Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. **2010**, 53, 5942-55	154
1634	Fragment library design: efficiently hunting drugs in chemical space. **2010**, 7, e147-202	30

1633	Data-mining patent literature for novel chemical reagents for use in medicinal chemistry design. **2010**, 1, 331	9
1632	Reducing the Risk of Drug Attrition Associated with Physicochemical Properties. **2010**, 45, 393-407	56
1631	In silico fragment-based drug design. **2010**, 5, 1047-65	19
1630	Computational analysis of structure-activity relationships. **2010**, 49, 113-60	14
1629	Cell-based apoptosis assays in oncology drug discovery. **2010**, 5, 583-96	8
1628	Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry. **2010**, 1, 309-318	61
1627	Overview on the Rule of Five. **2010**, Chapter 9, Unit 9.12	55
1626	Investigation of the relationship between topology and selectivity for druglike molecules. **2010**, 53, 7709-14	50
1625	Drug and drug candidate building block analysis. **2010**, 50, 55-67	83
1624	Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules. **2010**, 50, 2141-50	19
1623	Discovery of novel selective Sigma-1 ligands as cognitive enhancers. **2011**, 2, 655-660	5
1622	Impact of ion class and time on oral drug molecular properties. **2011**, 2, 91-105	72
1621	Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose. **2011**, 6, 913-20	20
1620	Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors. **2011**, 2, 715-9	12
1619	T-type calcium channels inhibitors: a patent review. **2011**, 21, 85-101	37
1618	Synthesis of arrays using low molecular weight MPEG-assisted Mitsunobu reaction. **2011**, 13, 280-5	13
1617	A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo. **2011**, 8, 1390-400	23
1616	Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers. **2011**, 22, 2304-16	32

1615	TIN-a combinatorial compound collection of synthetically feasible multicomponent synthesis products. **2011**, 51, 986-95	9
1614	Amino acids as the nitrogen-containing motifs in copper-catalyzed domino synthesis of N-heterocycles. **2011**, 76, 3846-52	127
1613	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. **2011**, 2, 91-96	140
1612	Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. **2011**, 54, 6691-703	58
1611	Copper-catalyzed aerobic oxidative intramolecular alkene C-H amination leading to N-heterocycles. **2011**, 13, 3694-7	71
1610	An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. **2011**, 2, 741-6	61
1609	Synthesis of a drug-like focused library of trisubstituted pyrrolidines using integrated flow chemistry and batch methods. **2011**, 13, 405-13	39
1608	Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. **2011**, 54, 709-18	17
1607	Virtual Screening of Chemical Space: From Generic Compound Collections to Tailored Screening Libraries. **2011**, 1-33	1
1606	Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds. **2011**, 51, 2482-95	45
1605	Chapter 3:The Learning and Evolution of Medicinal Chemistry against Kinase Targets. **2011**, 79-95	1
1604	Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141). **2011**, 54, 7860-83	27
1603	A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. **2011**, 54, 851-7	53
1602	Structure-based and property-compliant library design of 11β-HSD1 adamantyl amide inhibitors. **2011**, 685, 191-215	1
1601	Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. **2011**, 54, 719-33	34
1600	Using computational techniques in fragment-based drug discovery. **2011**, 493, 137-55	10
1599	ADME Properties and Their Dependence on Physicochemical Properties. **2011**, 165-181	3
1598	Lead generation and examples opinion regarding how to follow up hits. **2011**, 493, 383-419	31

1597	Effective progression of nuclear magnetic resonance-detected fragment hits. **2011**, 493, 447-68	4
1596	Chemoinformatics and Computational Chemical Biology. **2011**,	6
1595	Rational methods for the selection of diverse screening compounds. **2011**, 6, 208-17	80
1594	Quality by design in lead optimization: a new strategy to address productivity in drug discovery. **2011**, 11, 515-20	5
1593	Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. **2012**, 317, 83-114	44
1592	Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. **2011**, 24, 1420-56	371
1591	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo **2011**, 54, 3368-85	32
1590	Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate. **2011**, 2, 444-9	23
1589	Progress in structure based drug design for G protein-coupled receptors. **2011**, 54, 4283-311	191
1588	Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. **2011**, 2, 669	209
1587	Molecular obesity, potency and other addictions in drug discovery. **2011**, 2, 349-355	255
1586	Collaboration versus outsourcing: the need to think outside the box. **2011**, 3, 1995-2020	12
1585	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. **2011**, 54, 4781-92	61
1584	Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). **2011**, 21, 717-96	44
1583	Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors. **2011**, 46, 4808-19	20
1582	. **2011**,	13
1581	Collation and data-mining of literature bioactivity data for drug discovery. **2011**, 39, 1365-70	27
1580	Predicting in vivo safety characteristics using physiochemical properties and in vitro assays. **2011**, 3, 1503-11	8

1579	How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. **2011**, 163, 675-93		247
1578	Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers. **2011**, 77, 393-7		19
1577	Systems biology: Metabolites do social networking. **2011**, 7, 7-8		7
1576	Probing the links between in vitro potency, ADMET and physicochemical parameters. *Nature Reviews Drug Discovery*, **2011**, 10, 197-208	64.1	333
1575	Drug discovery: A question of library design. **2011**, 470, 42-3		92
1574	hERG potency estimates based upon dose solution analysis: What have we learned?. **2011**, 64, 251-7		5
1573	Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast. **2011**, 9, 70		54
1572	The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. **2011**, 16, 164-71		286
1571	Exploiting personalized information for reagent selection in drug design. **2011**, 16, 181-7		12
1570	Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience. **2011**, 16, 646-53		9
1569	A molecular informatics view on best practice in multi-parameter compound optimization. **2011**, 16, 555-68		16
1568	Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. **2011**, 16, 704-14		145
1567	Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. **2011**, 16, 822-30		215
1566	Drug discovery in the next decade: innovation needed ASAP. **2011**, 16, 779-92		59
1565	Evolution of the physicochemical properties of marketed drugs: can history foretell the future?. **2011**, 16, 976-84		43
1564	Kinetic efficiency: the missing metric for enhancing compound quality?. **2011**, 16, 910-3		36
1563	Identification of pyridazin-3-one derivatives as potent, selective histamine H□ receptor inverse agonists with robust wake activity. **2011**, 21, 5493-7		19
1562	Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds. **2011**, 21, 5487-92		15

1561	Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors. **2011**, 21, 5480-6	14
1560	Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H and the ion channel serotonin 5-HT A. **2011**, 21, 5460-4	30
1559	Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. **2011**, 21, 5673-9	47
1558	Acylglycinamides as inhibitors of glycine transporter type 1. **2011**, 21, 6176-9	2
1557	Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability. **2011**, 21, 5684-7	13
1556	Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles. **2011**, 21, 6108-11	11
1555	Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. **2011**, 21, 6031-5	4
1554	Discovery of pyrazoles as novel FPR1 antagonists. **2011**, 21, 6456-60	9
1553	Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists. **2011**, 21, 6409-13	13
1552	The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?. **2011**, 21, 6228-35	17
1551	Discovery, optimisation and in vivo evaluation of novel GPR119 agonists. **2011**, 21, 7310-6	15
1550	Fragment-Based Drug Discovery for Diseases of the Central Nervous System. **2011**, 179-192	
1549	Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen. **2011**, 51, 1048-63	26
1548	Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues. **2011**, 54, 5283-95	15
1547	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicy (PF-232798). **2011**, 54, 67-77	58
1546	1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis. **2011**, 54, 1724-39	24
1545	Preparing and Filtering Compound Databases for Virtual and Experimental Screening. **2011**, 35-59	6
1544	Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. **2011**, 54, 4207-18	50

1543	Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase. **2011**, 51, 2595-611		24
1542	What do medicinal chemists actually make? A 50-year retrospective. **2011**, 54, 6405-16		268
1541	The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. **2011**, 54, 3451-79		1494
1540	The influence of the 'organizational factor' on compound quality in drug discovery. *Nature Reviews Drug Discovery*, **2011**, 10, 749-65	64.1	132
1539	Understanding drug-likeness. **2011**, 1, 760-781		99
1538	Assessing the lipophilicity of fragments and early hits. **2011**, 25, 663-7		82
1537	Exploratory analysis of kinetic solubility measurements of a small molecule library. **2011**, 19, 4127-34		20
1536	Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds. **2011**, 3, 14		29
1535	Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements. **2011**, 100, 849-62		29
1534	Time-Trajectories in Efficiency Maps as Effective Guides for Drug Discovery Efforts. **2011**, 30, 137-44		4
1533	Predictivity of Simulated ADME AutoQSAR Models over Time. **2011**, 30, 256-66		29
1532	Molecular complexity and fragment-based drug discovery: ten years on. **2011**, 15, 489-96		129
1531	Efficiency of hit generation and structural characterization in fragment-based ligand discovery. **2011**, 15, 482-8		31
1530	Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats. **2011**, 19, 3039-53		23
1529	The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. **2011**, 21, 1588-92		11
1528	Discovery of small molecule human FPR1 receptor antagonists. **2011**, 21, 2991-7		16
1527	Structure-based design of thienobenzoxepin inhibitors of PI3-kinase. **2011**, 21, 4054-8		26
1526	Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone. **2011**, 21, 3557-62		34

1525	Selective non zinc binding inhibitors of MMP13. **2011**, 21, 4215-9	19
1524	Synthesis of 3,3-disubstituted oxetane building blocks. **2011**, 52, 565-567	10
1523	Fragment-based drug design: computational & experimental state of the art. **2011**, 14, 500-20	27
1522	Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery. **2011**, 138, 249-70	42
1521	Recent trends and observations in the design of high-quality screening collections. **2011**, 3, 751-66	47
1520	Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. **2011**, 108, 6817-22	81
1519	CCR5 Antagonists in HIV. **2011**, 207-238	
1518	Mapping of pharmacological space. **2011**, 6, 1-7	13
1517	Lessons from the Fersht laboratory could be vital for the future of the pharmaceutical industry. **2011**, 24, 65-7	
1516	Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. **2011**, 7, e1002036	65
1515	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. **2012**, 40, 2332-41	66
1514	Deployment of in silico and in vitro safety assays in early-stage drug discovery. **2012**, 4, 1211-3	4
1513	Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. **2012**, 12, 1500-13	40
1512	Molecular property filters describing pharmacokinetics and drug binding. **2012**, 19, 1646-62	31
1511	Improving risk assessment. **2012**, 4, 159ps22	12
1510	A leap into the chemical space of protein-protein interaction inhibitors. **2012**, 18, 4648-67	53
1509	Mechanism of Drug Action: Basic Concepts. **2012**, 9-38	
1508	Role of ADME Studies in Selecting Drug Candidates: Dependence of ADME Parameters on Physicochemical Properties. **2012**, 1	4

1507	Soft Drugs. **2012**, 77-258		
1506	Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2. **2012**, 55, 10532-9		9
1505	Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. *Nature Reviews Drug Discovery*, **2012**, 11, 909-22	64.1	450
1504	Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. **2012**, 22, 7106-9		8
1503	Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators. **2012**, 22, 6469-74		12
1502	Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329). **2012**, 55, 10136-47		33
1501	Structural optimization and evaluation of butenolides as potent antifouling agents: modification of the side chain affects the biological activities of compounds. **2012**, 28, 857-64		26
1500	DrugLogit: logistic discrimination between drugs and nondrugs including disease-specificity by assigning probabilities based on molecular properties. **2012**, 52, 2165-80		33
1499	Approach to the library of 3-hydroxy-1,5-dihydro-2H-pyrrol-2-ones through a three-component condensation. **2012**, 14, 631-5		23
1498	Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. **2012**, 22, 7326-9		43
1497	Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists. **2012**, 55, 10972-94		13
1496	Identification of novel adenosine A(2A) receptor antagonists by virtual screening. **2012**, 55, 1904-9		110
1495	Pharmacological Promiscuity and Molecular Properties. **2012**, 47-62		6
1494	Evaluating the enthalpic contribution to ligand binding using QM calculations: effect of methodology on geometries and interaction energies. **2012**, 10, 7053-61		7
1493	Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation. **2012**, 55, 5361-79		57
1492	Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. **2012**, 55, 9416-33		108
1491	Lead optimization of thiazolo[5,4-c]piperidines: 3-cyclobutoxy linker as a key spacer for H(3)R inverse agonists. **2012**, 7, 2087-92		3
1490	Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. **2012**, 19, 1300-12		129

1489	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors. **2012**, 22, 7615-22	11
1488	Privileged structures - dream or reality: preferential organization of azanaphthalene scaffold. **2012**, 19, 1921-45	46
1487	Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap. **2012**, 2, 3481	12
1486	Structural insights into the molecular basis of the ligand promiscuity. **2012**, 52, 2410-21	53
1485	Concise and efficient one-pot copper-catalyzed synthesis of H-pyrazolo[5,1-a]isoquinolines. **2012**, 2, 8258	25
1484	Reduction of acyl glucuronidation in a series of acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors: the discovery of AZD6925. **2012**, 3, 1264	11
1483	Enantiomeric pairs reveal that key medicinal chemistry parameters vary more than simple physical property based models can explain. **2012**, 3, 528	23
1482	Introduction: The Case for Polypharmacology. **2012**, 1-6	1
1481	Screening for Safety-Relevant Off-Target Activities. **2012**, 15-46	4
1480	Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication. **2012**, 3, 216-21	5
1479	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. **2012**, 55, 9831-7	157
1478	Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode. **2012**, 55, 3578-82	54
1477	New insights from structural biology into the druggability of G protein-coupled receptors. **2012**, 33, 249-60	150
1476	Experiences in fragment-based drug discovery. **2012**, 33, 224-32	205
1475	The contribution of physicochemical properties to multiple in vitro cytotoxicity endpoints. **2012**, 26, 613-20	21
1474	Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017). **2012**, 55, 5951-64	41
1473	Getting the MAX out of Computational Models: The Prediction of Unbound-Brain and Unbound-Plasma Maximum Concentrations. **2012**, 3, 515-9	2
1472	An approach to alicyclic ring-fused xanthines. **2012**, 68, 8564-8571	9

1471	Working with small molecules: rules-of-thumb of "drug likeness". **2012**, 803, 297-307	11
1470	Discovery of cis-N-(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene-2-carboximidamide: a 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities. **2012**, 55, 943-55	29
1469	The influence of lipophilicity in drug discovery and design. **2012**, 7, 863-75	336
1468	Data mining of protein-binding profiling data identifies structural modifications that distinguish selective and promiscuous compounds. **2012**, 52, 2454-61	23
1467	Going further than Lipinski's rule in drug design. **2012**, 7, 99-107	91
1466	Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1. **2012**, 55, 8745-56	46
1465	Drug-likeness analysis of traditional Chinese medicines: prediction of drug-likeness using machine learning approaches. **2012**, 9, 2875-86	88
1464	Influence of bromoethyl group on biological activity of 5-fluorouracil prodrug: Insights from X-ray crystallography and molecular docking. **2012**, 1027, 104-110	6
1463	Abbott Physicochemical Tiering (APT)--a unified approach to HTS triage. **2012**, 20, 4564-73	28
1462	Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential. **2012**, 22, 5134-40	5
1461	Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. **2012**, 22, 4599-604	76
1460	Discovery and optimization of novel purines as potent and selective CB2 agonists. **2012**, 22, 4962-6	14
1459	2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. **2012**, 22, 5392-5	16
1458	Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology. **2012**, 8, 683-94	137
1457	In vitro measurement of drug efficiency index to aid early lead optimization. **2012**, 101, 4155-69	28
1456	SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data. **2012**, 31, 555-568	8
1455	An Investigation of the Relationship Between Molecular Topology and CYP3A4 Inhibition for Drug-like Compounds. **2012**, 31, 719-23	
1454	Bioanalytical Support for Both In Vitro and In Vivo Assays Across Drug Discovery and Drug Development. **2012**, 1	

1453	Exploring aromatic chemical space with NEAT: novel and electronically equivalent aromatic template. **2012**, 52, 1114-23	15
1452	CHAPTER 18:Medicinal Chemistry Challenges in CNS Drug Discovery. **2012**, 465-509	5
1451	An Introduction to Solid-Phase Palladium Chemistry. **2012**, 1-21	
1450	Ligand-receptor interaction platforms and their applications for drug discovery. **2012**, 7, 969-88	81
1449	Discovery of phosphoinositide 3-kinases (PI3K) p110 isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. **2012**, 22, 6671-6	17
1448	(Q)SAR modeling and safety assessment in regulatory review. **2012**, 91, 529-34	56
1447	Portfolio Decisions in Early Development. **2012**, 26, 77-84	3
1446	Discovery of small molecule cancer drugs: successes, challenges and opportunities. **2012**, 6, 155-76	363
1445	Nanoparticle hydrophobicity dictates immune response. **2012**, 134, 3965-7	342
1444	Strategy in Drug Discovery and Development. **2012**, 452-458	
1443	Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. **2012**, 3, 596-601	16
1442	Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. **2012**, 55, 6624-8	47
1441	Protein-Protein Interactions as Drug Targets. **2012**, 1-55	3
1440	Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. **2012**, 55, 5151-64	57
1439	Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. **2012**, 22, 7523-9	9
1438	Spirocyclic sulfamides as secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors. **2012**, 55, 9224-39	51
1437	Minimizing Drug Exposure in the CNS while Maintaining Good Oral Absorption. **2012**, 3, 948-50	14
1436	A comparative analysis of the molecular topologies for drugs, clinical candidates, natural products, human metabolites and general bioactive compounds. **2012**, 3, 312-321	30

1435	Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. **2012**, 55, 8770-89		60
1434	What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics?. **2012**, 7, e51742		20
1433	Secretase Modulators: Can We Combine Potency with Safety?. **2012**, 2012, 295207		23
1432	. **2012**,		15
1431	Search for Molecular Basis of Antifungal Activity of Thiosemicarbazide Derivatives: A Combined in vitro Antifungal and Enzymatic Studies with in Silico Docking. **2012**, 10, 2-10		
1430	Hansch analysis 50 years on. **2012**, 2, 435-442		5
1429	Thermodynamics of fragment binding. **2012**, 52, 1039-45		55
1428	[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. **2012**, 55, 1127-36		62
1427	Impact of lipophilic efficiency on compound quality. **2012**, 55, 1252-60		126
1426	Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds. **2012**, 55, 3667-77		96
1425	Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. **2012**, 55, 3261-73		76
1424	Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). **2012**, 55, 4446-56		93
1423	Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents. **2012**, 3, 397-401		31
1422	Structural biology and drug discovery for protein-protein interactions. **2012**, 33, 241-8		130
1421	Finding the sweet spot: the role of nature and nurture in medicinal chemistry. *Nature Reviews Drug Discovery*, **2012**, 11, 355-65	64.1	295
1420	Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes. **2012**, 55, 3756-76		49
1419	Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. **2012**, 55, 3595-613		107
1418	Drug discovery: Chemical beauty contest. **2012**, 481, 455-6		204

1417	Chapter 2:Thermodynamics of Ligand Binding. **2012**, 23-79	4
1416	Chapter 5:Designing Multi-Target Drugs: In Vitro Panel Screening Biological Fingerprinting. **2012**, 66-85	1
1415	Chapter 10:The Challenges of Multi-Target Lead Optimization. **2012**, 141-154	12
1414	The developability of heteroaromatic and heteroaliphatic rings do some have a better pedigree as potential drug molecules than others?. **2012**, 3, 1062	128
1413	Towards the systematic exploration of chemical space. **2012**, 10, 17-28	54
1412	Disease-Specific Differentiation Between Drugs and Non-Drugs Using Principal Component Analysis of Their Molecular Descriptor Space. **2012**, 31, 369-83	7
1411	Oxadiazoles in medicinal chemistry. **2012**, 55, 1817-30	357
1410	Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. **2012**, 55, 5536-45	62
1409	Large-scale prediction and testing of drug activity on side-effect targets. **2012**, 486, 361-7	623
1408	Drug-like properties: guiding principles for the design of natural product libraries. **2012**, 75, 72-81	125
1407	Leitstruktur-orientierte Synthese: eine Alternative f die Synthesechemie. **2012**, 124, 1140-1149	67
1406	Structure-Based Macrocyclization Yields Hepatitis C Virus NS5B Inhibitors with Improved Binding Affinities and Pharmacokinetic Properties. **2012**, 124, 4715-4718	3
1405	Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties. **2012**, 51, 4637-40	31
1404	Discovery of small-molecule interleukin-2 inhibitors from a DNA-encoded chemical library. **2012**, 18, 7729-37	83
1403	Application of Barluenga Boronic Coupling (BBC) to the parallel synthesis of drug-like and drug fragment-like molecules. **2012**, 7, 233-6	30
1402	Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases. **2012**, 55, 5188-219	35
1401	Natural Products as Lead Compounds in Medicinal Chemistry. **2012**, 81-126	1
1400	Quantifying the chemical beauty of drugs. **2012**, 4, 90-8	664

1399	QSRR-based estimation of the retention time of opiate and sedative drugs by comprehensive two-dimensional gas chromatography. **2012**, 21, 1997-2005	12
1398	The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding. **2012**, 16, 27-51	15
1397	Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle. **2012**, 17, 56-62	54
1396	Drug discovery in the next decade: innovation needed ASAP. **2012**, 17 Suppl, S31-44	13
1395	Can we discover pharmacological promiscuity early in the drug discovery process?. **2012**, 17, 325-35	65
1394	Medicinal chemistry matters - a call for discipline in our discipline. **2012**, 17, 538-43	13
1393	Physicochemical profile of macrolides and their comparison with small molecules. **2012**, 47, 462-72	26
1392	Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). **2012**, 46, 8-16	15
1391	Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives. **2012**, 20, 1213-21	59
1390	Lead optimisation of pyrazoles as novel FPR1 antagonists. **2012**, 22, 532-6	10
1389	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. **2012**, 22, 271-7	12
1388	Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1. **2012**, 22, 2070-4	26
1387	Novel substituted 9-norbornylpurines and their activities against RNA viruses. **2012**, 22, 1963-8	7
1386	Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC. **2012**, 22, 2536-43	26
1385	Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active β-secretase modulators. **2012**, 22, 2906-11	27
1384	Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice. **2012**, 22, 2748-52	4
1383	Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists. **2012**, 22, 4198-202	5
1382	Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. **2012**, 22, 3873-8	32

1381	Size estimation of chemical space: how big is it?. **2012**, 64, 490-5	30
1380	Copper-catalyzed one-pot synthesis of imidazo/benzoimidazoquinazolinones by sequential Ullmann-type coupling and intramolecular C-H amidation. **2012**, 18, 1180-6	67
1379	Sulfonimidamides as sulfonamides bioisosteres: rational evaluation through synthetic, in vitro, and in vivo studies with β-secretase inhibitors. **2012**, 7, 396-9	55
1378	Scientific discovery as a combinatorial optimisation problem: how best to navigate the landscape of possible experiments?. **2012**, 34, 236-44	34
1377	Lead-oriented synthesis: a new opportunity for synthetic chemistry. **2012**, 51, 1114-22	295
1376	P2X receptor antagonists for pain management: examination of binding and physicochemical properties. **2012**, 8, 41-56	57
1375	Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. **2013**, 56, 6495-511	86
1374	Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1. **2013**, 23, 4517-22	14
1373	Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. **2013**, 23, 4571-8	17
1372	The AtlasCBS Application. **2013**, 49-62	
1371	General and efficient copper-catalyzed aerobic oxidative synthesis of N-fused heterocycles using amino acids as the nitrogen source. **2013**, 3, 15636	26
1370	Molecular computing: in situ computation of cell identity. **2013**, 8, 546-8	5
1369	Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches). **2013**, 453, 3-11	40
1368	An efficient, reusable copper-oxide/carbon-nanotube catalyst for N-arylation of imidazole. **2013**, 62, 135-148	74
1367	Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of Pseudomonas aeruginosa virulence. **2013**, 56, 6761-74	48
1366	Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. **2013**, 23, 5091-6	8
1365	Biological Activity of Molybdenum(II) Allyl Dicarbonyl Complexes with NN Coligands of Variable Aromatic Surface Area on Adherent and Non-adherent Human Cancer Cells. **2013**, 639, 1568-1576	12
1364	Applications of 3D-QSAR and structure-based pharmacophore modeling, virtual screening, ADMET, and molecular docking of putative MAPKAP-K2 (MK2) inhibitors. **2013**, 22, 4818-4829	2

1363	Polypharmacology - foe or friend?. **2013**, 56, 8955-71	306
1362	Through the looking glass: adventures in kinase inhibitor design and optimization. **2013**, 56, 1796-8	1
1361	A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding. **2013**, 56, 6845-57	11
1360	Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters. **2013**, 23, 5980-91	133
1359	Variational principles for mechanistic quantitative structure□activity relationship (QSAR) studies: application on uracil derivatives□anti-HIV action. **2013**, 24, 1873-1893	21
1358	6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35. **2013**, 56, 7084-99	25
1357	Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. **2013**, 56, 7049-59	23
1356	Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). **2013**, 56, 7025-48	155
1355	Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis. **2013**, 56, 6985-90	53
1354	The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. **2013**, 8, 1165-79	26
1353	Clear castable polyurethane elastomer for fabrication of microfluidic devices. **2013**, 13, 3956-64	85
1352	Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc. **2013**, 23, 6604-9	51
1351	The development of CNS-active LRRK2 inhibitors using property-directed optimisation. **2013**, 23, 3690-6	21
1350	The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations. **2013**, 23, 5992-6000	74
1349	A monomeric form of iNOS can rationalise observed SAR for inhibitors of dimerisation: quantum mechanics and docking compared. **2013**, 4, 180-186	2
1348	Increasing small molecule drug developability in sub-optimal chemical space. **2013**, 4, 673	46
1347	Synthesis, cytotoxicity and DNA binding of oxoazabenzo[de]anthracenes derivatives in colon cancer Caco-2 cells. **2013**, 69, 754-61	14
1346	Profound methyl effects in drug discovery and a call for new C-H methylation reactions. **2013**, 52, 12256-67	544

1345	The discovery of the benzazepine class of histamine H3 receptor antagonists. **2013**, 23, 6897-901		5
1344	Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. **2013**, 56, 9771-9		34
1343	Ausgeprägte Methyleffekte in der Wirkstoff-Forschung und der Bedarf an neuen C-H-Methylierungsreaktionen. **2013**, 125, 12480-12492		134
1342	Exploring the biologically relevant chemical space for drug discovery. **2013**, 53, 2820-8		33
1341	Chemical predictive modelling to improve compound quality. *Nature Reviews Drug Discovery*, **2013**, 12, 948-62	64.1	157
1340	De Novo Design by Fragment Growing and Docking. **2013**, 125-142		2
1339	Coping with Complexity in Molecular Design. **2013**, 57-77		1
1338	Hit and Lead Identification from Fragments. **2013**, 143-200		1
1337	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. **2013**, 56, 9934-54		96
1336	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate. **2013**, 18, 15276-87		16
1335	Pyranoxanthones: Synthesis, growth inhibitory activity on human tumor cell lines and determination of their lipophilicity in two membrane models. **2013**, 69, 798-816		28
1334	Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. **2013**, 56, 982-92		41
1333	Recent advances in lipid-based formulation technology. **2013**, 30, 2971-5		14
1332	Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy. **2013**, 56, 7073-83		36
1331	Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. **2013**, 23, 2134-9		21
1330	Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. **2013**, 56, 7590-607		75
1329	Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2013). **2013**, 48, 387-418		1
1328	Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists. **2013**, 23, 6118-22		10

1327	CHAPTER 7:HCV NS3/4a Protease Inhibitors: Simeprevir (TMC-435350), Vaniprevir (MK-7009) and MK-5172. **2013**, 189-247	1
1326	Using a fragment-based approach to target protein-protein interactions. **2013**, 14, 332-42	99
1325	. **2013**,	
1324	A conceptual framework for analysing and planning synthetic approaches to diverse lead-like scaffolds. **2013**, 49, 2383-93	45
1323	Synthesis of pyridopyrazine-1,6-diones from 6-hydroxypicolinic acids via a one-pot coupling/cyclization reaction. **2013**, 15, 642-5	18
1322	A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. **2013**, 5, 195-202	220
1321	On the origins of drug polypharmacology. **2013**, 4, 80-87	102
1320	Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease. **2013**, 56, 220-40	14
1319	The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. **2013**, 18, 218-39	120
1318	Principles and applications of halogen bonding in medicinal chemistry and chemical biology. **2013**, 56, 1363-88	792
1317	Divergent ionic liquid supported synthesis of isolable guanidine linked quinoxalinone and benzodiamine. **2013**, 54, 454-458	4
1316	Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119. **2013**, 56, 301-19	27
1315	Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries. **2013**, 23, 1407-11	21
1314	Non-benzimidazole containing inhibitors of respiratory syncytial virus. **2013**, 23, 827-33	7
1313	Contributions of molecular properties to drug promiscuity. **2013**, 56, 1789-95	109
1312	Inflation of correlation in the pursuit of drug-likeness. **2013**, 27, 1-13	60
1311	Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. **2013**, 18, 1014-24	52
1310	In silico physicochemical parameter predictions. **2013**, 10, 1224-35	31

1309	Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. **2013**, 56, 2270-82	36
1308	N-Methylierung von Peptiden und Proteinen: ein wichtiges Element f□ die Regulation biologischer Funktionen. **2013**, 125, 268-283	60
1307	N-methylation of peptides and proteins: an important element for modulating biological functions. **2013**, 52, 254-69	296
1306	A chemogenomic analysis of ionization constants--implications for drug discovery. **2013**, 8, 242-55	32
1305	A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents. **2013**, 8, 226-30	21
1304	Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR). **2013**, 1830, 5112-8	9
1303	N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. **2013**, 23, 3713-8	12
1302	Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. **2013**, 23, 6239-42	9
1301	Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. **2013**, 23, 6019-24	28
1300	Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics. **2013**, 23, 4511-6	19
1299	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi. **2013**, 23, 3576-9	14
1298	Investigation of the influence of molecular topology on ligand binding. **2013**, 40, 22-9	0
1297	The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems. **2013**, 283-381	15
1296	Copper-Mediated Cyclization Reactions: New Entries to Heterocycles. **2013**, 531-588	1
1295	Emerging technologies for metabolite generation and structural diversification. **2013**, 23, 5471-83	48
1294	Hydantoin based inhibitors of MMP13--discovery of AZD6605. **2013**, 23, 4705-12	17
1293	1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling. **2013**, 49, 423-33	13
1292	One-Pot Synthesis of Pyrrolo[3,4-a]indolizine-1,3-diones through [3+2] Cycloaddition-Oxidation Reaction Catalyzed by CuII Salt and O2 as the Oxidant. **2013**, 2013, 2020-2026	17

1291	Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. **2013**, 68, 68-94	186
1290	Design and optimization of selective protein kinase C (PKC) inhibitors for the treatment of autoimmune diseases. **2013**, 56, 1799-810	35
1289	Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. **2013**, 138, 333-408	604
1288	Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. **2013**, 56, 1946-60	28
1287	How are fragments optimized? A retrospective analysis of 145 fragment optimizations. **2013**, 56, 2478-86	52
1286	Triazolopyrimidinones as secretase modulators: structure ctivity relationship, modulator profile, and in vivo profiling. **2013**, 4, 422	9
1285	Escape from Flatland 2: complexity and promiscuity. **2013**, 4, 515	519
1284	Practical purification of hydrophilic fragments and lead/drug-like molecules by reverse phase flash chromatography: tips, tricks and contemporary developments. **2013**, 18, 148-54	5
1283	Considering the impact drug-like properties have on the chance of success. **2013**, 18, 659-66	79
1282	Systematic exploration of dual-acting modulators from a combined medicinal chemistry and biology perspective. **2013**, 56, 1197-210	13
1281	Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. **2013**, 56, 3033-47	93
1280	On the solubility and lipophilicity of metallacarborane pharmacophores. **2013**, 10, 1751-9	39
1279	Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. **2013**, 280, 5957-80	84
1278	Nitroimidazolyl hydrazones are better amoebicides than their cyclized 1,3,4-oxadiazoline analogues: In vitro studies and Lipophilic efficiency analysis. **2013**, 64, 190-9	17
1277	Copper-Catalyzed Selective Oxidative Acylation of Secondary Anilines with Ethyl Glyoxalate: Domino Synthesis of Indoline-2,3-diones. **2013**, 355, 1169-1176	35
1276	Identification of false positives in HTS hits to lead The application of Bayesian models in HTS triage to rapidly deliver a series of selective TRPV4 antagonists. **2013**, 4, 244-251	15
1275	Hit expansion approaches using multiple similarity methods and virtualized query structures. **2013**, 53, 1057-66	12
1274	Biophysical fragment screening of the -adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. **2013**, 56, 3446-55	129

1273	Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. **2013**, 4, 113-7	25
1272	De novo design and optimization of Aurora A kinase inhibitors. **2013**, 4, 1229	22
1271	Copper-catalyzed N-arylation and aerobic oxidative CH/CH coupling: one-pot synthesis of indoloimidazoquinoline derivatives. **2013**, 3, 8211	16
1270	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. **2013**, 4, 441-445	50
1269	Small and colorful stones make beautiful mosaics: fragment-based chemogenomics. **2013**, 18, 323-30	26
1268	A chemistry wiki to facilitate and enhance compound design in drug discovery. **2013**, 18, 141-7	8
1267	Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. **2013**, 56, 4156-80	112
1266	Design of potent poxvirus inhibitors of the heterodimeric processivity factor required for viral replication. **2013**, 56, 3235-46	52
1265	Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. **2013**, 10, 1191-206	53
1264	8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35. **2013**, 56, 5182-97	28
1263	Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity. **2013**, 4, 456	22
1262	Self-assembled Tat nanofibers as effective drug carrier and transporter. **2013**, 7, 5965-77	160
1261	Hydration properties of ligands and drugs in protein binding sites: tightly-bound, bridging water molecules and their effects and consequences on molecular design strategies. **2013**, 53, 1388-405	53
1260	Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. **2013**, 56, 4521-36	56
1259	Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. **2013**, 56, 4764-85	48
1258	Synthesis, cytotoxicity and in vitro antileishmanial activity of naphthothiazoles. **2013**, 81, 749-56	7
1257	Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists. **2013**, 56, 5142-50	70
1256	Fused thiazolyl alkynes as potent mGlu5 receptor positive allosteric modulators. **2013**, 23, 4037-43	8

1255	Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics. **2013**, 4, 627-31	16
1254	Reaction methodology: Speed dating for reactions. **2013**, 5, 554-5	7
1253	Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. **2013**, 56, 5722-33	28
1252	Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective 1 receptor ligands. **2013**, 56, 3656-65	31
1251	Inhibitors of HIV-1 attachment. Part 8: the effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors. **2013**, 23, 203-8	32
1250	Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists. **2013**, 4, 95-100	10
1249	A facile method for the synthesis of pyridazino[4,5-b][1,4]thiazine-diones via Smiles rearrangement. **2013**, 54, 3253-3255	10
1248	Model structure-activity relationship studies of potential tropane 5HT, 5HT, and D receptor ligands. **2013**, 22, 3148-3153	3
1247	Recent progress on the discovery of non-peptidic direct renin inhibitors for the clinical management of hypertension. **2013**, 8, 673-90	15
1246	Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors. **2013**, 4, 1148	5
1245	Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists. **2013**, 10, 1153-61	17
1244	Tactics to Avoid Inhibition of Cytochrome P450s. **2013**, 107-158	2
1243	Efficient Combination of Environment Change and Alchemical Perturbation within the Enveloping Distribution Sampling (EDS) Scheme: Twin-System EDS and Application to the Determination of Octanol-Water Partition Coefficients. **2013**, 9, 1334-46	14
1242	Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors. **2013**, 4, 1305	11
1241	Content Development Strategies for the Successful Implementation of Data Mining Technologies. **2013**, 209-240	
1240	The significance of acid/base properties in drug discovery. **2013**, 42, 485-96	181
1239	Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor. **2013**, 4, 52-67	23
1238	Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. **2013**, 5, 113-5	79

1237	Medicinal chemistry of glucagon-like peptide receptor agonists. **2013**, 52, 45-96	9
1236	High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. **2013**, 58, 388-96	220
1235	The Impact of Natural Products Upon Cancer Chemotherapy. **2013**, 3-15	
1234	Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013). **2013**, 85, 1725-1758	10
1233	Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. **2013**, 136, 242-9	69
1232	Front-loading natural-product-screening libraries for log P: background, development, and implementation. **2013**, 10, 524-37	17
1231	In silico optimization of a fragment-based hit yields biologically active, high-efficiency inhibitors for glutamate racemase. **2013**, 8, 1681-9	9
1230	High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?. **2013**, 8, 1449-53	8
1229	AqF026 is a pharmacologic agonist of the water channel aquaporin-1. **2013**, 24, 1045-52	43
1228	4-Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading. **2013**, 125, 14305-14309	6
1227	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. **2013**, 52, 14055-9	90
1226	APPLICATIONS OF CHEMINFORMATICS IN PHARMACEUTICAL RESEARCH. **2013**, 291-320	
1225	A framework for grouping nanoparticles based on their measurable characteristics. **2013**, 8 Suppl 1, 45-56	25
1224	Use of natural products as chemical library for drug discovery and network pharmacology. **2013**, 8, e62839	224
1223	A new in vivo screening paradigm to accelerate antimalarial drug discovery. **2013**, 8, e66967	24
1222	Cyclodextrin formulation of the marine natural product pseudopterosin A uncovers optimal pharmacodynamics in proliferation studies of human umbilical vein endothelial cells. **2013**, 11, 3258-71	11
1221	The role of medicinal chemistry in the drug discovery process. **2013**, 119-134	
1220	In silico modeling of human 2C-adrenoreceptor interaction with filamin-2. **2014**, 9, e103099	10

1219	Drug-likeness approach of 2-aminopyrimidines as histamine H3 receptor ligands. **2014**, 8, 1499-513	10
1218	Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. **2014**, 6, 179-204	27
1217	Structural Biology and Anticancer Drug Design. **2014**, 121-141	1
1216	Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the β2-adrenoceptor. **2014**, 85, 608-17	76
1215	A Trip Through Chemical Space: Why Life Has Evolved the Chemistry That It Has. **2014**, 371-394	
1214	Fixierung cyclischer Peptide: Mimetika von Proteinstrukturmotiven. **2014**, 126, 13234-13257	67
1213	Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. **2014**, 6, 246-61	25
1212	Cytotoxic compounds from Laurencia pacifica. **2014**, 4, 8	13
1211	Scaffold hopping with virtual screening from IP3 to a drug-like partial agonist of the inositol trisphosphate receptor. **2014**, 15, 2774-82	8
1210	The ChEMBL bioactivity database: an update. **2014**, 42, D1083-90	1052
1209	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. **2014**, 5, 231	114
1208	Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign. **2014**, 8, e3253	45
1207	Construction and Computation with Nucleic Acids on the Cell Surface. **2014**, 157-173	
1206	The ChEMBL database: a taster for medicinal chemists. **2014**, 6, 361-4	32
1205	Lost in Translation (LiT): IUPHAR Review 6. **2014**, 171, 2269-90	7
1204	Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase. **2014**, 24, 5683-5687	17
1203	A reversed sulfonamide series of selective RORc inverse agonists. **2014**, 24, 5769-5776	23
1202	Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. **2014**, 21, 1476-85	47

1201	Efficient exploration of chemical space by fragment-based screening. **2014**, 116, 82-91	88
1200	Fragment-based approaches to the discovery of kinase inhibitors. **2014**, 548, 69-92	9
1199	In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. **2014**, 57, 9901-14	41
1198	Structure-based drug design for G protein-coupled receptors. **2014**, 53, 1-63	57
1197	On the Relationship between Molecular Hit Rates in High-Throughput Screening and Molecular Descriptors. **2014**, 19, 727-37	14
1196	Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. **2014**, 83, 38-51	24
1195	Identification of tertiary sulfonamides as RORc inverse agonists. **2014**, 24, 2182-7	27
1194	The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists. **2014**, 24, 72-6	13
1193	Molecular structure, vibrational and electronic properties of 4-Phenyl-3H-1,3-thiazol-2-ol using density functional theory and comparison of drug efficacy of keto and enol forms by QSAR analysis. **2014**, 132, 568-81	5
1192	Towards the realisation of lead-oriented synthesis. **2014**, 19, 813-9	39
1191	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. **2014**, 19, 171-82	122
1190	HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase. **2014**, 24, 1315-21	31
1189	Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds. **2014**, 76, 427-34	12
1188	Natural products as lead structures: chemical transformations to create lead-like libraries. **2014**, 19, 215-21	69
1187	Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications. **2014**, 76, 193-244	292
1186	Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. **2014**, 53, 4056-75	32
1185	Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness. **2014**, 24, 2236-9	9
1184	Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. **2014**, 24, 2288-94	17

1183	Matched molecular pair analysis: significance and the impact of experimental uncertainty. **2014**, 57, 3786-802	50
1182	Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. **2014**, 59, 69-82	17
1181	Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. **2014**, 75, 354-74	46
1180	Current Social, Clinical, and Scientific Environment of Pharmaceutical R&D. **2014**, 1-21	
1179	Multiparameter Optimization of ADMET for Drug Design. **2014**, 145-166	1
1178	Drug-Induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools. **2014**, 433-465	3
1177	Validity of ligand efficiency metrics. **2014**, 5, 616-8	85
1176	Fragment-based lead discovery and design. **2014**, 54, 693-704	96
1175	The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. **2014**, 5, 335-9	102
1174	The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1. **2014**, 9, 1378-86	18
1173	The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2. **2014**, 9, 1387-96	15
1172	Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. **2014**, 57, 1276-88	90
1171	Synthesis and characterization of a porphyrazine-Gd(III) MRI contrast agent and in vivo imaging of a breast cancer xenograft model. **2014**, 9, 313-22	15
1170	Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide. **2014**, 73, 46-55	34
1169	Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP). **2014**, 57, 2773-88	52
1168	Physical Properties in Drug Design. **2014**, 1-68	9
1167	Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione □secretase modulators. **2014**, 57, 1046-62	25
1166	The ErbB/HER family of protein-tyrosine kinases and cancer. **2014**, 79, 34-74	750

1165	Identification of a novel conformationally constrained glucagon receptor antagonist. **2014**, 24, 839-44		14
1164	Synthesis of 1-(pyrrolidin-2-ylmethyl)-1H-azoles and their piperidine-derived homologues. **2014**, 12, 67-73		1
1163	Finding the rules for successful drug optimisation. **2014**, 19, 680-7		26
1162	Structure-based drug design of chromone antagonists of the adenosine A2A receptor. **2014**, 5, 571-575		22
1161	Rings in drugs. **2014**, 57, 5845-59		1190
1160	The role of ligand efficiency metrics in drug discovery. *Nature Reviews Drug Discovery*, **2014**, 13, 105-21	64.1	649
1159	Toward lead-oriented synthesis: one-pot version of Castagnoli condensation with nonactivated alicyclic anhydrides. **2014**, 16, 146-53		24
1158	Data-driven medicinal chemistry in the era of big data. **2014**, 19, 859-68		101
1157	Translational paradigms in pharmacology and drug discovery. **2014**, 87, 189-210		31
1156	Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. **2014**, 57, 173-99		198
1155	Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept. **2014**, 57, 309-24		25
1154	Studies on molecular properties prediction and histamine H3 receptor affinities of novel ligands with uracil-based motifs. **2014**, 86, 578-88		9
1153	Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. **2014**, 57, 10176-91		43
1152	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. **2014**, 57, 10144-61		146
1151	Advancing the Drug Discovery and Development Process. **2014**, 126, 9280-9292		16
1150	Novel natural and biomimetic ligands to enhance selectivity of membrane processes for solute-solute separations: beyond nature's logistic legacy. **2014**, 89, 354-371		3
1149	Novel tactics for designing water-soluble molecules in drug discovery. **2014**, 9, 1421-33		32
1148	Synthesis of iminosugar derivatives presenting naphthyl and alkyl amine interacting groups and binding to somatostatin receptors. **2014**, 5, 1150-1158		7

1147	Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. **2014**, 57, 8540-62	33
1146	Lead Discovery and Lead Modification. **2014**, 19-122	5
1145	Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. **2014**, 5, 1266-1279	19
1144	The essential roles of chemistry in high-throughput screening triage. **2014**, 6, 1265-90	93
1143	Identification and optimisation of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11╫hydroxysteroid dehydrogenase type 1 (11╫HSD1). **2014**, 5, 57-63	6
1142	Drug safety testing paradigm, current progress and future challenges: an overview. **2014**, 34, 576-94	49
1141	Ligand efficiency-based support vector regression models for predicting bioactivities of ligands to drug target proteins. **2014**, 54, 2751-63	16
1140	Recent advances in the structure-based rational design of TNKSIs. **2014**, 10, 2783-99	18
1139	Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. **2014**, 9, 1546-55	10
1138	Development of N-methyl-(2-arylquinolin-4-yl)oxypropanamides as leads to PET radioligands for translocator protein (18 kDa). **2014**, 57, 6240-51	19
1137	New Hits as Antagonists of GPR103 Identified by HTS. **2014**, 5, 527-32	5
1136	Drug Discovery vs hERG. **2014**, 225-259	4
1135	Current strategies for designing antidotes against botulinum neurotoxins. **2014**, 9, 319-33	15
1134	GPR103 antagonists demonstrating anorexigenic activity in vivo: design and development of pyrrolo[2,3-c]pyridines that mimic the C-terminal Arg-Phe motif of QRFP26. **2014**, 57, 5935-48	13
1133	Improving the use of ranking in virtual screening against HIV-1 integrase with triangular numbers and including ligand profiling with antitargets. **2014**, 54, 3172-85	10
1132	Which three-dimensional characteristics make efficient inhibitors of protein-protein interactions?. **2014**, 54, 3067-79	33
1131	Acidic and basic drugs in medicinal chemistry: a perspective. **2014**, 57, 9701-17	122
1130	Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts. **2014**, 5, 1235-9	16

1129	Small molecule ghrelin receptor inverse agonists and antagonists. **2014**, 57, 8671-91	29
1128	Gold/acid-co-catalyzed direct microwave-assisted synthesis of fused azaheterocycles from propargylic hydroperoxides. **2014**, 20, 3384-93	16
1127	Investigations of amide bond variation and biaryl modification in analogues of α7 nAChR agonist SEN12333. **2014**, 84, 200-5	2
1126	Progesterone-targeted magnetic resonance imaging probes. **2014**, 25, 1428-37	6
1125	Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. **2014**, 111, 10911-6	141
1124	Synthesis of tripeptides containing D-Trp substituted at the indole ring, assessment of opioid receptor binding and in vivo central antinociception. **2014**, 57, 6861-6	17
1123	Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. **2014**, 24, 3891-7	42
1122	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. **2014**, 24, 3719-23	6
1121	Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. **2014**, 6, 739-45	4
1120	2-Aminothiazole derivatives as antimycobacterial agents: Synthesis, characterization, in vitro and in silico studies. **2014**, 87, 643-56	31
1119	Statins and breast cancer prognosis: evidence and opportunities. **2014**, 15, e461-8	128
1118	Synthesis of novel bridged dinitrogen heterocycles and their evaluation as potential fragments for the design of biologically active compounds. **2014**, 70, 7854-7864	16
1117	Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus. **2014**, 57, 8608-21	33
1116	Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. **2014**, 21, 1115-42	336
1115	Constraining cyclic peptides to mimic protein structure motifs. **2014**, 53, 13020-41	277
1114	Size does matter! Label-free detection of small molecule-protein interaction. **2014**, 406, 4033-51	23
1113	Advancing the drug discovery and development process. **2014**, 53, 9128-40	53
1112	Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization. **2014**, 57, 3484-93	39

1111	Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists. **2014**, 57, 6128-40	21
1110	Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. **2014**, 57, 6679-703	61
1109	The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists. **2014**, 24, 3285-90	13
1108	Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. **2014**, 5, 474-9	43
1107	Regioselective synthesis of fused imidazo[1,2-a]pyrimidines via intramolecular C-N bond formation/6-endo-dig cycloisomerization. **2014**, 79, 6905-12	34
1106	A modular lead-oriented synthesis of diverse piperazine, 1,4-diazepane and 1,5-diazocane scaffolds. **2014**, 12, 2584-91	44
1105	What does the aromatic ring number mean for drug design?. **2014**, 9, 995-1003	36
1104	Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists. **2014**, 24, 4450-4454	11
1103	Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment. **2014**, 11, 964-73	41
1102	Applying conformational selection theory to improve crossdocking efficiency in 3-phosphoinositide dependent protein kinase-1. **2014**, 82, 436-51	1
1101	Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. **2014**, 24, 1681-4	21
1100	Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists. **2014**, 22, 1649-66	21
1099	Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groups. **2014**, 24, 3104-7	4
1098	Ligand efficiency metrics considered harmful. **2014**, 28, 699-710	45
1097	Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. **2014**, 6, 617-39	30
1096	Biosynthonics: Charting the Future Role of Biocatalysis and Metabolic Engineering in Drug Discovery. **2014**, 53, 18597-18610	3
1095	Many approved drugs have bioactive analogs with different target annotations. **2014**, 16, 847-59	12
1094	Hepatitis C replication inhibitors that target the viral NS4B protein. **2014**, 57, 2107-20	39

1093	Diversity-oriented synthetic strategies applied to cancer chemical biology and drug discovery. **2014**, 19, 17221-55	24
1092	Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter. **2014**, 141, 28-36	27
1091	Herzregeneration: Chancen und Aufgaben f□ die Wirkstoff-Forschung mit neuartigen chemischen und therapeutischen Methoden oder Agentien. **2014**, 126, 4138-4159	2
1090	Combining Organometallic Reagents, the Sulfur Dioxide Surrogate DABSO, and Amines: A One-Pot Preparation of Sulfonamides, Amenable to Array Synthesis. **2015**, 127, 1184-1187	46
1089	Introduction. **2015**, 1-9	1
1088	Elements for the Development of Strategies for Compound Library Enhancement. **2015**, 11-36	
1087	Advances in the Understanding of Drug Properties in Medicinal Chemistry. **2015**, 305-322	1
1086	ADME Profiling. **2015**, 353-377	1
1085	Virtual Screening. **2015**, 251-280	2
1084	Thermodynamics-Guided Optimizations in Medicinal Chemistry. **2015**, 63-80	
1083	The Binding Thermodynamics of Drug Candidates. **2015**, 1-13	6
1082	Structural Optimization of Ghrelin Receptor Inverse Agonists to Improve Lipophilicity and Avoid Mechanism-Based CYP3A4 Inactivation. **2015**, 63, 825-32	1
1081	Designing CNS Drugs for Optimal Brain Exposure. **2015**, 385-424	2
1080	Crizotinib (Xalkori): The First-in-Class ALK/ROS Inhibitor for Non-small Cell Lung Cancer. **2015**, 119-156	0
1079	- Ligand-Based Drug Discovery and Design. **2015**, 116-139	2
1078	Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity. **2015**, 5, 14836	14
1077	Compound Attrition at the Preclinical Phase. **2015**, 46-82	
1076	Thermodynamic Profiling of Carbonic Anhydrase Inhibitors. **2015**, 137-154	

1075	In silico ADME/T modelling for rational drug design. **2015**, 48, 488-515	137
1074	Potent Synergy between Spirocyclic Pyrrolidinoindolinones and Fluconazole against Candida albicans. **2015**, 10, 1672-86	14
1073	Metal-Free Oxidative C H Amidation of N,N?-Diarylureas with PhI(OAc)2: Synthesis of Benzimidazol-2-one Derivatives. **2015**, 2015, 5869-5875	20
1072	Copper-Catalyzed Domino Synthesis of Benzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-ones using Cyanamide as a Building Block. **2015**, 357, 3961-3968	3
1071	Computer-Aided Drug Design of Bioactive Natural Products. **2015**, 15, 1780-800	48
1070	Fragment-based drug discovery and molecular docking in drug design. **2015**, 16, 11-25	41
1069	Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. **2015**, 10, e0139588	13
1068	Identification of New Molecular Entities (NMEs) as Potential Leads against Tuberculosis from Open Source Compound Repository. **2015**, 10, e0144018	14
1067	. **2015**,	6
1066	. **2015**,	5
1065	. **2015**,	17
1064	Computer-aided drug discovery. **2015**, 4,	33
1063	. **2015**,	5
1062	Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS). **2015**, 25, 2496-500	9
1061	Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. **2015**, 71, 485-99	5
1060	A systematic approach to diverse, lead-like scaffolds from disubstituted amino acids. **2015**, 51, 11174-7	48
1059	Panel docking of small-molecule libraries - Prospects to improve efficiency of lead compound discovery. **2015**, 33, 941-7	16
1058	Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities. **2015**, 23, 4544-4560	10

1057	Irreversible endo-selective diels-alder reactions of substituted alkoxyfurans: a general synthesis of endo-cantharimides. **2015**, 21, 6107-14	23
1056	Molecular Obesity, Potency and Other Addictions in Drug Discovery. **2015**, 183-196	2
1055	Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors. **2015**, 58, 5121-36	26
1054	2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor. **2015**, 25, 2707-12	4
1053	Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae. **2015**, 1, 533-43	38
1052	The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space. **2015**, 822, 187-94	14
1051	Exploring S1 plasticity and probing S1' subsite of mammalian aminopeptidase N/CD13 with highly potent and selective aminobenzosuberone inhibitors. **2015**, 23, 3192-207	7
1050	Molecular Property Design: Does Everyone Get It?. **2015**, 6, 722-5	80
1049	Design of pyrazolo-pyrimidines as 11β-HSD1 inhibitors through optimisation of molecular electrostatic potential. **2015**, 6, 926-934	3
1048	Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists. **2015**, 25, 2907-12	49
1047	Virology: MicroRNA-lipid one-upmanship. **2015**, 11, 905-6	1
1046	Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). **2015**, 58, 9480-97	103
1045	Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods. **2015**, 29, 1109-22	6
1044	Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease. **2015**, 25, 1086-91	22
1043	The application of in silico drug-likeness predictions in pharmaceutical research. **2015**, 86, 2-10	190
1042	A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinases. **2015**, 58, 1563-8	16
1041	Molecular recognition in chemical and biological systems. **2015**, 54, 3290-327	380
1040	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents. **2015**, 25, 1301-5	10

1039	Long-chain alkyltriazoles as antitumor agents: synthesis, physicochemical properties, and biological and computational evaluation. **2015**, 24, 430-441	5
1038	Synthesis and structure-activity relationship study of a new series of selective (1) receptor ligands for the treatment of pain: 4-aminotriazoles. **2015**, 58, 2441-51	33
1037	Preclinical characterization of acyl sulfonimidamides: potential carboxylic acid bioisosteres with tunable properties. **2015**, 10, 455-60	35
1036	Iron-catalyzed aerobic oxidative functionalization of sp3 C H bonds: a versatile strategy for the construction of N-heterocycles. **2015**, 5, 2197-2202	43
1035	Fluorine in medicinal chemistry. **2015**, 54, 65-133	132
1034	Is there a link between selectivity and binding thermodynamics profiles?. **2015**, 20, 86-94	37
1033	TAK1 selective inhibition: state of the art and future opportunities. **2015**, 7, 23-33	24
1032	A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligands. **2015**, 29, 59-66	6
1031	Molekulare Erkennung in chemischen und biologischen Systemen. **2015**, 127, 3341-3382	95
1030	Fragment-based design of kinase inhibitors: a practical guide. **2015**, 1289, 157-83	3
1029	Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase. **2015**, 58, 5437-44	46
1028	Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. **2015**, 22, 689-703	103
1027	Clinical ECG Assessment. **2015**, 229, 435-68	6
1026	Strategies in the Search for New Lead Compounds or Original Working Hypotheses. **2015**, 73-99	6
1025	Compound Properties and their Influence on Drug Quality. **2015**, 379-393	5
1024	Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist. **2015**, 58, 5308-22	51
1023	Interpreting physicochemical experimental data sets. **2015**, 29, 779-94	2
1022	A facile synthesis and evaluation of new biomolecule-based coumarin thiazoline hybrids as potent anti-tubercular agents with cytotoxicity, DNA cleavage and X-ray studies. **2015**, 5, 64566-64581	25

1021	Pharmaceuticals that contain polycyclic hydrocarbon scaffolds. **2015**, 44, 7737-63		127
1020	Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys. **2015**, 6, 861-5		16
1019	MOARF, an Integrated Workflow for Multiobjective Optimization: Implementation, Synthesis, and Biological Evaluation. **2015**, 55, 1169-80		24
1018	An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nature Reviews Drug Discovery*, **2015**, 14, 475-86	64.1	713
1017	ESKAPEing the labyrinth of antibacterial discovery. *Nature Reviews Drug Discovery*, **2015**, 14, 529-42	64.1	340
1016	The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits. **2015**, 58, 7140-63		22
1015	Confocal Raman Microscopy for in Situ Measurement of Octanol-Water Partitioning within the Pores of Individual C18-Functionalized Chromatographic Particles. **2015**, 87, 5340-7		12
1014	Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. **2015**, 58, 6733-46		27
1013	Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists. **2015**, 25, 2041-5		2
1012	New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. **2015**, 25, 2308-13		34
1011	Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists. **2015**, 6, 1054-1064		5
1010	Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors. **2015**, 58, 3892-909		25
1009	Anti-trypanosomal activities and structural chemical properties of selected compound classes. **2015** , 114, 501-12		6
1008	Increasing the delivery of next generation therapeutics from high throughput screening libraries. **2015**, 26, 104-10		29
1007	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. **2015**, 58, 4888-904		170
1006	Privileged scaffolds in lead generation. **2015**, 10, 781-90		51
1005	Engineering G Protein-Coupled Receptors for Drug Design. **2015**, 1-18		2
1004	Promiscuity and selectivity of bitter molecules and their receptors. **2015**, 23, 4082-91		67

1003	A Functional Group Approach for Prediction of APPI Response of Organic Synthetic Targets. **2015**, 26, 1221-32	4
1002	Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys. **2015**, 6, 573-8	20
1001	Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. **2015**, 97, 202-13	60
1000	Discovery of oxybisbenzoylamides as a new class of antimalarial agents. **2015**, 6, 1173-1177	3
999	Lead-oriented synthesis: Investigation of organolithium-mediated routes to 3-D scaffolds and 3-D shape analysis of a virtual lead-like library. **2015**, 23, 2680-94	20
998	Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery. **2015**, 10, 331-43	17
997	How many molecules does it take to tell a story? Case studies, language, and an epistemic view of medicinal chemistry. **2015**, 10, 949-56	12
996	Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I). **2015**, 58, 3060-82	21
995	Fluorine in drug design: a case study with fluoroanisoles. **2015**, 10, 715-26	74
994	Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs). **2015**, 25, 2037-40	5
993	Structure-activity relationship studies of SEN12333 analogues: determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs. **2015**, 95, 277-301	9
992	Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). **2015**, 58, 8182-99	33
991	Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. **2015**, 23, 6666-72	28
990	On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. **2015**, 7, 1339-77	98
989	Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. **2015**, 58, 9027-40	26
988	Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent. **2015**, 25, 5687-93	3
987	Highly functionalized tetrahydropyridines are cytotoxic and selective inhibitors of human puromycin sensitive aminopeptidase. **2015**, 106, 26-33	10
986	Chemical libraries: How dark is HTS dark matter?. **2015**, 11, 904-5	11

985	Batch and Flow Synthesis of Pyrrolo[1,2-a]-quinolines via an Allene-Based Reaction Cascade. **2015**, 80, 10806-16	36
984	Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors. **2015**, 25, 5258-64	17
983	Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. **2015**, 58, 8877-95	29
982	Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity. **2015**, 58, 7057-75	14
981	Novel Pyrazolo[1,5-a]pyrimidines as Translocator Protein 18 kDa (TSPO) Ligands: Synthesis, in Vitro Biological Evaluation, [(18)F]-Labeling, and in Vivo Neuroinflammation PET Images. **2015**, 58, 7449-64	29
980	A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis. **2015**, 1, 604-14	17
979	Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. **2015**, 583, 105-19	78
978	Discovery of high affinity inhibitors of -myristoyltransferase. **2015**, 6, 1761-1766	18
977	A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs). **2015**, 20, 748-59	22
976	Price-Focused Analysis of Commercially Available Building Blocks for Combinatorial Library Synthesis. **2015**, 17, 600-7	39
975	Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists. **2015**, 25, 4109-13	10
974	Evidence for the in vitro bioactivation of aminopyrazole derivatives: trapping reactive aminopyrazole intermediates using glutathione ethyl ester in human liver microsomes. **2015**, 28, 1747-52	5
973	Ligand efficiency metrics: why all the fuss?. **2015**, 7, 1363-5	19
972	The impact of binding thermodynamics on medicinal chemistry optimizations. **2015**, 7, 1285-303	7
971	Intestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions. **2015**, 6, 935-59	29
970	Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. **2015**, 58, 7485-500	48
969	Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists. **2015**, 23, 7158-64	20
968	Bioactive Benzofuran derivatives: A review. **2015**, 97, 483-504	323

967	Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action. **2015**, 6, 276-81	65
966	A Prospective Method To Guide Small Molecule Drug Design. **2015**, 92, 836-842	7
965	Targeting G-quadruplex nucleic acids with heterocyclic alkaloids and their derivatives. **2015**, 97, 538-51	51
964	Advancing drug discovery: a pharmaceutics perspective. **2015**, 104, 865-71	9
963	Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists. **2015**, 6, 156-61	12
962	Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. **2015**, 58, 613-24	48
961	Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases. **2015**, 58, 897-911	33
960	Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. **2015**, 25, 75-82	16
959	CNS drug design: balancing physicochemical properties for optimal brain exposure. **2015**, 58, 2584-608	318
958	Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases. **2015**, 10, 296-303	31
957	Combining organometallic reagents, the sulfur dioxide surrogate DABSO, and amines: a one-pot preparation of sulfonamides, amenable to array synthesis. **2015**, 54, 1168-71	123
956	Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. **2015**, 58, 401-18	53
955	Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. **2015**, 23, 241-63	17
954	A unified lead-oriented synthesis of over fifty molecular scaffolds. **2015**, 13, 859-65	43
953	Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. **2015**, 58, 376-400	39
952	Computational prediction of drug solubility in fasted simulated and aspirated human intestinal fluid. **2015**, 32, 578-89	36
951	Designing novel building blocks is an overlooked strategy to improve compound quality. **2015**, 20, 11-7	141
950	Quantitative Structure–Activity Relationships. **2016**, 163-192	4

949	Prediction Rules for Rapid Property Profiling from Structure. **2016**, 29-38	
948	Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies. **2016**, 10, 265	49
947	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. **2016**, 17,	54
946	Successful application of virtual screening and molecular dynamics simulations against antimalarial molecular targets. **2016**, 111, 721-730	15
945	Molecular Mechanisms Controlling HIV Transcription and Latency Implications for Therapeutic Viral Reactivation. **2016**,	2
944	Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model. **2016**, 33, 2604-16	22
943	Lead Generation Based on Compound Collection Screening. **2016**, 93-132	0
942	Fragment-Based Lead Generation. **2016**, 133-158	
941	Advances in Activity Cliff Research. **2016**, 35, 181-91	20
940	Novel Nucleolipids of Pyrimidine D-Ribonucleosides: Combinatorial Synthesis, Spectroscopic Characterization, and Cytostatic/Cytotoxic Activities. **2016**, 13, 160-80	6
939	Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. **2016**, 11, 850-61	20
938	Lead Quality. **2016**, 451-486	3
937	Lead Generation Paved the Way for the Discovery of a Novel H 3 Inverse Agonist Clinical Candidate. **2016**, 513-546	
936	Molecular Recognition and Its Importance for Fragment-Based Lead Generation and Hit-to-Lead. **2016**, 367-400	
935	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors. **2016**, 59, 7212-22	24
934	Preparation of benzimidazole N-oxides by a two-step continuous flow process. **2016**, 52, 952-957	5
933	Big Data from Pharmaceutical Patents: A Computational Analysis of Medicinal Chemists' Bread and Butter. **2016**, 59, 4385-402	202
932	Investigating the Influence of (Deoxy)fluorination on the Lipophilicity of Non-UV-Active Fluorinated Alkanols and Carbohydrates by a New log P Determination Method. **2016**, 128, 684-688	25

931	Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. **2016**, 26, 2303-7	8
930	Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors. **2016**, 26, 2952-2956	5
929	Solubility-driven lead optimisation: Recent examples and personal perspectives. **2016**, 26, 2975-2979	11
928	Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability. **2016**, 59, 5284-96	39
927	N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity. **2016**, 11, 687-701	21
926	Drug discovery in focal and segmental glomerulosclerosis. **2016**, 89, 1211-20	11
925	Investigating the Influence of (Deoxy)fluorination on the Lipophilicity of Non-UV-Active Fluorinated Alkanols and Carbohydrates by a New log P Determination Method. **2016**, 55, 674-8	84
924	Cell permeability beyond the rule of 5. **2016**, 101, 42-61	140
923	The mycotoxin definition reconsidered towards fungal cyclic depsipeptides. **2016**, 34, 114-35	21
922	Polarity, selectivity and performance of hydrophilic organic/salt-containing aqueous two-phase system on counter-current chromatography for polar compounds. **2016**, 1448, 49-57	6
921	Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. **2016**, 59, 3689-704	26
920	Lipophilicity and biomimetic properties measured by HPLC to support drug discovery. **2016**, 130, 35-54	51
919	Secondary pharmacology: screening and interpretation of off-target activities - focus on translation. **2016**, 21, 1232-42	26
918	A divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool. **2016**, 52, 7209-12	65
917	The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. **2016**, 30, 381-9	7
916	Optimization of amide-based EP3 receptor antagonists. **2016**, 26, 2670-5	6
915	Computer Simulation Studies of the Mechanism of Hydrotrope-Assisted Solubilization of a Sparingly Soluble Drug Molecule. **2016**, 120, 3540-50	17
914	Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor. **2016**, 7, 933-938	18

913	Compound Prioritization in Single-Concentration Screening Data Using Ligand Efficiency Indexes. **2016**, 56, 1705-13		2
912	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. **2016**, 59, 9672-9685		45
911	Where clinical chemistry meets medicinal chemistry. Systematic analysis of physico-chemical properties predicts stability of common used drugs in gel separator serum tubes. **2016**, 462, 23-27		17
910	No Denying It: Medicinal Chemistry Training Is in Big Trouble. **2016**, 59, 10859-10864		21
909	Network Pharmacology and Epilepsy. **2016**, 351-364		1
908	The Evolving Role of the Medicinal Chemist. **2016**, 55, 193-226		0
907	Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986). **2016**, 59, 9457-9472		36
906	Novel approach of fragment-based lead discovery applied to renin inhibitors. **2016**, 24, 6066-6074		3
905	IDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug data. **2016**, 8, 33		13
904	Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties. **2016**, 26, 4455-4461		14
903	Recent progress on nuclear receptor RORγ modulators. **2016**, 26, 4387-4393		66
902	Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors. **2016**, 59, 8306-25		31
901	Biophysics in drug discovery: impact, challenges and opportunities. *Nature Reviews Drug Discovery*, **2016**, 15, 679-98	64.1	209
900	Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. **2016**, 116, 176-87		12
899	Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Research for Improving the Chance of Success of Drug Design and Discovery. **2016**, 5, 357-68		13
898	Small-Molecule Safety Lead Optimization. **2016**, 13-26		
897	Ligand Efficiency Metrics and their Use in Fragment Optimizations. **2016**, 75-98		1
896	Fragment-Based Discovery of Inhibitors of Lactate Dehydrogenase A. **2016**, 391-424		

895	Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. **2016**, 59, 7584-97	21
894	Prediction of cyclohexane-water distribution coefficients for the SAMPL5 data set using molecular dynamics simulations with the OPLS-AA force field. **2016**, 30, 1045-1058	16
893	Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead. **2016**, 7, 913-918	12
892	New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms. **2016**, 26, 4518-4522	16
891	Partitioning into Colloidal Structures of Fasted State Intestinal Fluid Studied by Molecular Dynamics Simulations. **2016**, 32, 12732-12740	17
890	A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials. **2016**, 23, 1294-1301	66
889	Modeling Organic Anion-Transporting Polypeptide 1B1 Inhibition to Elucidate Interaction Risks in Early Drug Design. **2016**, 105, 3214-3220	2
888	Tetrazolone as an acid bioisostere: application to marketed drugs containing a carboxylic acid. **2016**, 14, 9343-9347	10
887	Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. **2016**, 26, 4211-5	3
886	Computational approaches for innovative antiepileptic drug discovery. **2016**, 11, 1001-16	8
885	Lipophilicity in Drug Development: Too Much or Not Enough?. **2016**, 18, 1095-1100	8
884	Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. **2016**, 21, 1719-1727	55
883	Molecular descriptor data explain market prices of a large commercial chemical compound library. **2016**, 6, 28521	8
882	Synthesis of Allenes through Triazole Gold(III) Catalysed Rearrangement of Propargyl Vinyl Ethers. **2016**, 40, 645-647	3
881	The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. **2016**, 59, 10084-10099	52
880	The Many Facets of Screening Library Design. **2016**, 345-364	1
879	Installing amino acids and peptides on N-heterocycles under visible-light assistance. **2016**, 6, 20068	61
878	Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression. **2016**, 7, 1635-1640	4

877	Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. **2016**, 70, 275-283	4
876	CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. **2016**, 25, 1377-1392	24
875	The Strategies and Politics of Successful Design, Make, Test, and Analyze (DMTA) Cycles in Lead Generation. **2016**, 487-512	1
874	GPR81 HTS Case Study. **2016**, 597-650	
873	Metal-Free □C(sp3)□H Functionalized Oxidative Cyclization of Tertiary N,N-Diarylamino Alcohols: Construction of N,N-Diarylaminotetrahydropyran Scaffolds. **2016**, 5, 232-239	8
872	Pr□ise Lipophilie(log P)-Messungen geben Auskunft □er feine stereoelektronische Effekte in der Fluorchemie. **2016**, 128, 3922-3924	3
871	Design, synthesis and cytotoxic activities of novel 2,5-diketopiperazine derivatives. **2016**, 121, 500-509	14
870	Thiazolo[3,2-a]benzimidazol-3(2H)-one derivatives: Structure-activity relationships of selective nucleotide pyrophosphatase/phosphodiesterase1 (NPP1) inhibitors. **2016**, 24, 3157-65	12
869	Low potency toxins reveal dense interaction networks in metabolism. **2016**, 10, 19	2
868	Phosphine-catalyzed [4+2] annulations of □aminonitriles with allenoates: Synthesis of functionalized tetrahydropyridines. **2016**, 32, 385-389	7
867	Uncoupling the Structure-Activity Relationships of □ Adrenergic Receptor Ligands from Membrane Binding. **2016**, 59, 5780-9	17
866	Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors. **2016**, 59, 5879-93	65
865	Lipophilicity. **2016**, 39-50	3
864	Lead Properties. **2016**, 283-289	4
863	The Flip-Flop Diffusion Mechanism across Lipids in a Hybrid Bilayer Membrane. **2016**, 110, 2451-2462	16
862	Chemical named entity recognition in patents by domain knowledge and unsupervised feature learning. **2016**, 2016,	17
861	Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists. **2016**, 26, 3441-6	14
860	Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors. **2016**, 26, 3518-24	9

859	Vibrational studies, NMR analysis, modeling of electronic and thermodynamical parameters of 1,3-bis(4-benzamido)triazene. **2016**, 90, 1391-1404	
858	Introduction: Learnings from the Past Characteristics of Successful Leads. **2016**, 1-12	
857	Accurate Lipophilicity (log P) Measurements Inform on Subtle Stereoelectronic Effects in Fluorine Chemistry. **2016**, 55, 3858-60	19
856	Cyclic peptide oral bioavailability: Lessons from the past. **2016**, 106, 901-909	68
855	Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain. **2016**, 59, 1350-6	47
854	Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives. **2016**, 59, 1116-39	14
853	Compound high-quality criteria: a new vision to guide the development of drugs, current situation. **2016**, 21, 573-84	27
852	Synthesis and evaluation of colletoic acid core derivatives. **2016**, 110, 126-32	6
851	Tools for Early Prediction of Drug Loading in Lipid-Based Formulations. **2016**, 13, 251-61	52
850	Methodology of oral formulation selection in the pharmaceutical industry. **2016**, 87, 136-63	41
849	Discovery of the imidazole-derived GPR40 agonist AM-3189. **2016**, 26, 15-20	14
848	Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. **2016**, 59, 194-205	42
847	Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) Agonist. **2016**, 59, 3264-71	24
846	New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents. **2016**, 115, 41-52	9
845	Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design. **2016**, 59, 3034-45	14
844	Optimization of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase Based on Group Efficiency Analysis. **2016**, 11, 38-42	19
843	An Additive Definition of Molecular Complexity. **2016**, 56, 462-70	54
842	Compound annotation with real time cellular activity profiles to improve drug discovery. **2016**, 11, 269-80	3

841	Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery. **2016**, 13, 609-20	42
840	Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket. **2016**, 26, 1605-1611	3
839	Molecular inflation, attrition and the rule of five. **2016**, 101, 22-33	116
838	Profiling the estimated plasma concentrations of 215 marketed oral drugs. **2016**, 7, 706-719	11
837	Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action. **2016**, 59, 5587-603	52
836	Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs. **2016**, 15, 50	17
835	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. **2016**, 29, 564-616	112
834	One-pot synthesis of highly functionalized pyrimido[1,2-b]indazoles via 6-endo-dig cyclization. **2016**, 6, 24610-24616	29
833	Computational prediction of formulation strategies for beyond-rule-of-5 compounds. **2016**, 101, 6-21	92
832	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. **2016**, 59, 2841-6	17
831	Design and evaluation of novel glutaminase inhibitors. **2016**, 24, 1819-39	39
830	Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening. **2016**, 56, 234-47	17
829	Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature. **2016**, 59, 5604-21	46
828	Innovative polymeric system (IPS) for solvent-free lipophilic drug transdermal delivery via dissolving microneedles. **2016**, 223, 118-125	43
827	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors. **2016**, 26, 849-853	9
826	Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. **2016**, 29, 452-72	20
825	Toxicology Strategies for Drug Discovery: Present and Future. **2016**, 29, 473-504	106
824	Quantifying, Visualizing, and Monitoring Lead Optimization. **2016**, 59, 4189-201	25

823	A new paradigm for navigating compound property related drug attrition. **2016**, 21, 72-81	30
822	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. **2016**, 59, 2849-78	199
821	Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. **2016**, 31, 538-45	36
820	Structurally Enabled Discovery of Adenosine A Receptor Antagonists. **2017**, 117, 21-37	54
819	Biophysical properties of the clinical-stage antibody landscape. **2017**, 114, 944-949	259
818	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. **2017**, 60, 3533-3551	40
817	Fluorine multipolar interaction: Toward elucidating its energetics in binding recognition. **2017**, 198, 47-53	16
816	Molecular docking, discovery, synthesis, and pharmacological properties of new 6-substituted-2-(3-phenoxyphenyl)-4-phenyl quinoline derivatives; an approach to developing potent DNA gyrase inhibitors/antibacterial agents. **2017**, 25, 1448-1455	43
815	Design considerations to minimize the impact of drug absorption in polymer-based organ-on-a-chip platforms. **2017**, 17, 681-690	76
814	Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. **2017**, 31, 201-211	69
813	Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase [PI3K]Inhibitors. **2017**, 60, 1534-1554	6
812	Designing safer oral drugs. **2017**, 8, 571-577	2
811	Next generation of small molecules in inflammatory bowel disease. **2017**, 66, 199-209	78
810	Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. **2017**, 60, 5235-5266	53
809	Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites. **2017**, 8, 350-354	16
808	Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. **2017**, 8, 316-320	21
807	Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X receptor antagonists. **2017**, 130, 433-439	16
806	Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. **2017**, 8, 823-840	46

805	How to identify and eliminate compounds with a risk of high clinical dose during the early phase of lead optimisation in drug discovery. **2017**, 110, 37-50	9
804	Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action. **2017**, 25, 3298-3314	7
803	Pyrazolo[3,4-]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4. **2017**, 8, 1246-1254	4
802	Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles. **2017**, 60, 6771-6780	12
801	Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. **2017**, 7, 46277	71
800	Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment Based Drug Design. **2017**, 60, 5521-5542	84
799	Structure-based design and synthesis of acyclic and substituted heterocyclic phosphonates linearly linked to thiazolobenzimidazoles as potent hydrophilic antineoplastic agents. **2017**, 71, 1961-1973	5
798	From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors. **2017**, 27, 2974-2981	30
797	Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study. **2017**, 25, 3500-3511	17
796	Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. **2017**, 60, 4386-4402	42
795	Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective. **2017**, 87 Suppl 3, S1-S15	21
794	Discover Toxicology: An Early Safety Assessment Approach. **2017**, 119-162	2
793	Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. **2017**, 30, 1219-1229	25
792	Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP receptor antagonists. **2017**, 25, 3406-3430	1
791	Amine promiscuity and toxicology analysis. **2017**, 27, 653-657	5
790	Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: Pyridone- and pyrimidinone-derived systems. **2017**, 27, 3219-3225	3
789	Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo. **2017**, 60, 5717-5735	18
788	Small Molecule Inhibitors of ALK. **2017**, 435-467	3

787	Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines. **2017**, 27, 3897-3904	2
786	Multicomplex-based pharmacophore modeling coupled with molecular dynamics simulations: An efficient strategy for the identification of novel inhibitors of PfDHODH. **2017**, 75, 413-423	17
785	Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5. **2017**, 12, 1033-1044	27
784	The Need for Restructuring the Disordered Science of Amorphous Drug Formulations. **2017**, 34, 1754-1772	63
783	A theoretical study of atropisomerism in N-(2-methylphenyl)-N?-(2-methylphenyl) thiourea and its inclusion in the ‡cyclodextrin. **2017**, 88, 199-207	
782	Efficacy and cytotoxicity in cell culture of novel ‡hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. **2017**, 144, 164-172	25
781	Synthesis and cardiomyocyte protection activity of crocetin diamide derivatives. **2017**, 121, 106-111	6
780	Bioactive Coumarins and Xanthones From Calophyllum Genus and Analysis of Their Druglikeness and Toxicological Properties. **2017**, 53, 277-307	6
779	Lipophilicity and biomimetic properties to support drug discovery. **2017**, 12, 885-896	48
778	Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl)pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer. **2017**, 7, 27737-27746	10
777	Orally Absorbed Cyclic Peptides. **2017**, 117, 8094-8128	209
776	Thiazole-Based ‡Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Molecular Interactions. **2017**, 12, 1070-1080	5
775	Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes. **2017**, 60, 5209-5215	8
774	The safety of non-biological treatments in Ulcerative Colitis. **2017**, 16, 779-789	17
773	Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket. **2017**, 8, 504-509	14
772	Sustainable Practices in Medicinal Chemistry Part 2: Green by Design. **2017**, 60, 5955-5968	14
771	Mechanistic prediction of food effects for Compound A tablet using PBPK model. **2017**, 24, 603-609	7
770	Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain. **2017**, 60, 5349-5363	24

769	CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. **2017**, 60, 5943-5954	59
768	Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors. **2017**, 60, 2485-2497	82
767	Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors. **2017**, 27, 1955-1961	11
766	Structure-Based Design of Tricyclic NF-B Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K). **2017**, 60, 627-640	43
765	Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis. **2017**, 37, 1051-1094	20
764	Identification of novel PAD4 inhibitors based on a pharmacophore model derived from transition state coordinates. **2017**, 72, 88-95	1
763	Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. **2017**, 8, 239-244	45
762	Sulfonimidamide in medizinischer Chemie und Agrochemie. **2017**, 129, 4160-4170	29
761	Sulfonimidamides in Medicinal and Agricultural Chemistry. **2017**, 56, 4100-4109	85
760	Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options. **2017**, 106, 921-929	62
759	Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists. **2017**, 60, 362-372	14
758	Innovation in Small-Molecule-Druggable Chemical Space: Where are the Initial Modulators of New Targets Published?. **2017**, 57, 2741-2753	5
757	Theoretical assessment of calix[n]arene as drug carriers for second generation tyrosine kinase inhibitors. **2017**, 247, 448-455	6
756	Computational Macrocyclization: From de novo Macrocycle Generation to Binding Affinity Estimation. **2017**, 12, 1866-1872	19
755	Discovery and evaluation of Ca3.2-selective T-type calcium channel blockers. **2017**, 27, 5326-5331	3
754	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. **2017**, 60, 8369-8384	88
753	Photoredox Generation of Carbon-Centered Radicals Enables the Construction of 1,1-Difluoroalkene Carbonyl Mimics. **2017**, 56, 15073-15077	186
752	From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y receptor. **2017**, 27, 4849-4853	15

751	Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma. **2017**, 60, 8466-8481	5
750	Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase. **2017**, 60, 9040-9052	13
749	Improvement in aqueous solubility achieved via small molecular changes. **2017**, 27, 5100-5108	24
748	Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based Approaches. **2017**, 12, 2906-2914	26
747	Optimization of Substrate-Analogue Furin Inhibitors. **2017**, 12, 1953-1968	25
746	Toward a generalized computational workflow for exploiting transient pockets as new targets for small molecule stabilizers: Application to the homogentisate 1,2-dioxygenase mutants at the base of rare disease Alkaptonuria. **2017**, 70, 133-141	12
745	Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. **2017**, 12, 1087-1104	50
744	Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. **2017**, 46, 627-644	18
743	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. **2017**, 60, 7725-7744	14
742	Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. **2017**, 60, 8083-8102	29
741	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). **2017**, 60, 9162-9183	48
740	Ligand-Targeted Drug Delivery. **2017**, 117, 12133-12164	267
739	Visible-Light-Mediated Aerobic Oxidation of N-Alkylpyridinium Salts under Organic Photocatalysis. **2017**, 139, 14237-14243	57
738	Thermodynamics in Drug Discovery. **2017**, 7-28	3
737	Hitoyol A and B, Two Norsesquiterpenoids from the Basidiomycete Coprinopsis cinerea. **2017**, 19, 4030-4033	13
736	Bistacrines as potential antitrypanosomal agents. **2017**, 25, 4526-4531	4
735	Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma. **2017**, 138, 602-615	6
734	Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?. **2017**, 60, 7206-7212	35

733	FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery. **2017**, 33, 3658-3660		141
732	A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces. **2017**, 57, 2250-2272		11
731	Cu2O/Cs2CO3/DMF: An efficient catalytic system for N-arylation of imidazole with aryl halides under ligand-free conditions. **2017**, 47, 1797-1803		6
730	Nitro-substituted tetrahydroindolizines and homologs: Design, kinetics, and mechanism of □glucosidase inhibition. **2017**, 27, 3980-3986		19
729	Design and synthesis of 2,6-di(substituted phenyl)thiazolo[3,2-b]-1,2,4-triazoles as □glucosidase and □amylase inhibitors, co-relative Pharmacokinetics and 3D QSAR and risk analysis. **2017**, 94, 499-513		17
728	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. **2017**, 57, 2143-2151		20
727	Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates. **2017**, 60, 7764-7780		4
726	3-Aryl-3-(isoxazol-3-yl)propanoic Acids and 2-Aryloxyacetic Acids as Potent GPR40 Agonists. **2017**, 38, 838-844		
725	Discovery of 2,3-Dihydro-1H-indene Derivatives as Novel GPR40 Agonists. **2017**, 38, 861-868		0
724	Cancer systems biology: Harnessing off-target effects. **2017**, 13, 1204-1205		5
723	Overview of Macrocycles in Clinical Development and Clinically Used. **2017**, 411-499		2
722	The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties. **2017**, 60, 9676-9690		11
721	Iridium-Catalyzed Enantioselective Synthesis of Dihydroimidazoquinazolinones by Elaborate Tuning of Chiral Cyclic Ligands. **2017**, 19, 6376-6379		11
720	Optimization of a Macrocyclic Ghrelin Receptor Agonist (Part II). **2017**, 545-558		0
719	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. **2017**, 32, 9-25		110
718	Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. *Nature Reviews Drug Discovery*, **2017**, 16, 787-810	64.1	82
717	Review and analysis of FDA approved drugs using lipid-based formulations. **2017**, 43, 1743-1758		108
716	Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. **2017**, 138, 458-479		25

715	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. **2017**, 22, 1478-1488	4
714	Kit-like 18F-labeling of an estradiol derivative as a potential PET imaging agent for estrogen receptor-positive breast cancer. **2017**, 312, 599-607	3
713	Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. **2017**, 137, 58-66	12
712	Fragment-to-Lead Medicinal Chemistry Publications in 2015. **2017**, 60, 89-99	36
711	Review: biologically active pyrazole derivatives. **2017**, 41, 16-41	364
710	An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer. **2017**, 118, 1412-1422	8
709	Glycerol assisted eco-friendly strategy for the facile synthesis of 4,4?-(arylmethylene)bis(3-methyl-1H-pyrazol-5-ols) and 2-aryl-2,3-dihydroquinazolin-4(1H)-ones under catalyst-free conditions. **2017**, 43, 1767-1782	24
708	Photoredox Generation of Carbon-Centered Radicals Enables the Construction of 1,1-Difluoroalkene Carbonyl Mimics. **2017**, 129, 15269-15273	34
707	The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications. **2017**, 46, 7706-7756	240
706	Tryptophan-Containing Non-Cationizable Opioid Peptides - a new chemotype with unusual structure and in vivo activity. **2017**, 9, 2099-2115	3
705	Fragment-Based Lead Discovery. **2017**, 371-439	9
704	QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors. **2017**, 10, S1081-S1094	14
703	In vitro membrane binding and protein binding (IAM MB/PB technology) to estimate in vivo distribution: applications in early drug discovery. **2017**, 5, 14	16
702	Kinetics, Thermodynamics, and Ligand Efficiency Metrics in Drug Discovery. **2017**, 180-211	1
701	Application of thin-layer chromatography to evaluate the lipophilicity of 5,8-quinolinedione compounds. **2017**, 30, 219-224	6
700	Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. **2017**, 8, 155	14
699	Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp Centers Enhance Target Selectivity. **2017**, 8, 552	10
698	Protein degradation: a validated therapeutic strategy with exciting prospects. **2017**, 61, 517-527	24

697	Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds. **2017**, 10,	24
696	Drug discovery. **2017**, 281-420	1
695	Medicinal Chemistry Case History: Osimertinib (AZD9291). **2017**, 1-32	
694	Recent Advances in Medicinal Chemistry of Antisense Oligonucleotides. **2017**, 216-232	5
693	Synthesis, Molecular Properties Estimations, and Dual Dopamine D and D Receptor Activities of Benzothiazole-Based Ligands. **2017**, 5, 64	7
692	Contemporary Considerations for Discovering a Successful Medicine. **2017**, 560-576	
691	Hit and Lead Generation Strategies. **2017**, 33-63	1
690	Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms. **2017**, 12, e0176590	30
689	Screening a protein kinase inhibitor library against Plasmodium falciparum. **2017**, 16, 446	9
688	Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment. **2017**, 94-115	2
687	Protein□Protein Interaction Inhibitors in Cancer. **2017**, 154-201	0
686	Fragment-Based Drug Design: Strategic Advances and Lessons Learned. **2017**, 212-232	5
685	The Discovery of p97 Inhibitors. **2017**, 113-137	
684	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. **2017**, 64-93	
683	The Discovery and Development of Seletalisib : A Potent and Selective PI3K□Inhibitor for Inflammatory Diseases. **2017**, 366-407	1
682	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. **2018**, 61, 2227-2245	119
681	Copper-Catalyzed Chan-Lam Cyclopropylation of Phenols and Azaheterocycles. **2018**, 83, 3417-3425	25
680	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. **2018**, 61, 4317-4334	53

679	Mechanistic understanding and binding analysis of a novel Schiff base palladium (II) complex with ‖lactoglobulin and human serum albumin. **2018**, 262, 218-229	9
678	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. **2018**, 61, 6421-6467	48
677	Practical application of ligand efficiency metrics in lead optimisation. **2018**, 26, 3006-3015	34
676	SAR Studies of -[2-(1-Tetrazol-5-yl)phenyl]benzamide Derivatives as Potent G Protein-Coupled Receptor-35 Agonists. **2018**, 9, 422-427	4
675	An explorative study on potent Gram-negative specific LpxC inhibitors: CoMFA, CoMSIA, HQSAR and molecular docking. **2018**, 38, 151-165	2
674	Accessing lipophilicity of drugs with biomimetic models: A comparative study using liposomes and micelles. **2018**, 115, 369-380	18
673	Computational exploration of reactive fragment for mechanism-based inhibition of xanthine oxidase. **2018**, 864, 58-67	4
672	Oral drug suitability parameters. **2018**, 9, 460-470	
671	Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. **2018**, 77, 429-435	13
670	Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists. **2018**, 26, 1598-1608	12
669	Salen complex of Cu(II) supported on superparamagnetic Fe3O4@SiO2 nanoparticles: an efficient and magnetically recoverable catalyst for N-arylation of imidazole with aryl halides. **2018**, 149, 1101-1109	8
668	Ionic liquids for addressing unmet needs in healthcare. **2018**, 3, 7-25	82
667	Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified?. **2018**, 23, 605-615	53
666	Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold. **2018**, 26, 703-711	6
665	Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs. **2018**, 31, 494-505	17
664	Homology modelling, molecular docking, and molecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A. **2018**, 11, 246	14
663	Lipophilic Efficiency as an Important Metric in Drug Design. **2018**, 61, 6401-6420	111
662	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). **2018**, 118, 67-79	11

661	Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling. **2018**, 61, 3641-3659		13
660	A study of the properties, reactivity and anticancer activity of novel N-methylated-3-thiazolyl or 3-thienyl carbazoles and their Pd(II) and Pt(II) complexes. **2018**, 184, 134-145		3
659	Structure-Based Optimization of Small-Molecule Inhibitors for the Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. **2018**, 61, 2989-3007		23
658	Bicyclo[2.2.1]heptane containing ,'-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents.. **2018**, 8, 11061-11069		6
657	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. **2018**, 477-496		1
656	Physicochemical Properties and Structural Alerts. **2018**, 61-76		2
655	The Current State of Peptide Drug Discovery: Back to the Future?. **2018**, 61, 1382-1414		458
654	Fragment-to-Lead Medicinal Chemistry Publications in 2016. **2018**, 61, 1774-1784		27
653	Medicinal chemistry in drug discovery in big pharma: past, present and future. **2018**, 23, 219-234		41
652	Organ-on-a-Chip Systems for Women's Health Applications. **2018**, 7, 1700550		25
651	Ein Instrumentarium von -RGD-Integrin-Inhibitoren: Wirkstoffsuche, Herausforderungen und Mglichkeiten. **2018**, 130, 3354-3379		12
650	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response. **2018**, 26, 1435-1447		3
649	An -RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. **2018**, 57, 3298-3321		64
648	Drug repurposing of novel quinoline acetohydrazide derivatives as potent COX-2 inhibitors and anti-cancer agents. **2018**, 1154, 437-444		17
647	Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring. **2018**, 72, 170-180		29
646	Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors. **2018**, 61, 265-285		28
645	Automating drug discovery. *Nature Reviews Drug Discovery*, **2018**, 17, 97-113	64.1	275
644	Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors. **2018**, 145, 606-621		13

643	In silico ligand-based modeling of hBACE-1 inhibitors. **2018**, 91, 817-827	3
642	Synthesis of 2,3-di(Ehydroxyalkyl)quinolines from anilines and cyclic enols using sequential cycloaddition/aromatization reactions. **2018**, 59, 22-25	6
641	Lipophilicity assessement in drug discovery: Experimental and theoretical methods applied to xanthone derivatives. **2018**, 1072, 182-192	18
640	Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors. **2018**, 61, 1415-1424	14
639	Iatrogenic QT Prolongation. **2018**, 383-418	
638	Synthesis, chemical characterization and cancer cell growth-inhibitory activities of Cu(ii) and Ru(iii) aliphatic and aromatic dithiocarbamato complexes. **2018**, 47, 15477-15486	17
637	Solving a 3D Structural Puzzle. **2018**,	0
636	Synthesis and antimycobacterial activity of (+)-usnic acid conjugates. **2018**, 351, e1800177	6
635	Application of NOEs and 3JHH-Couplings in 3D Structure Determination. **2018**, 27-96	
634	Axially Chiral Cyclic Diphosphine Ligand-Enabled Palladium-Catalyzed Intramolecular Asymmetric Hydroarylation. **2018**, 10, 11-22	5
633	Chemical probes for dynein. **2018**, 172-191	2
632	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. **2018**, 61, 9534-9550	20
631	Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. **2018**, 625-650	
630	Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility. **2018**, 61, 11169-11182	68
629	Hit-to-Lead: Hit Validation and Assessment. **2018**, 610, 265-309	8
628	High-throughput screening for selective appetite modulators: A multibehavioral and translational drug discovery strategy. **2018**, 4, eaav1966	33
627	Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities. **2018**, 9, 1035	18
626	Novel Imidazole and Methoxybenzylamine Growth Inhibitors Affecting Salmonella Cell Envelope Integrity and its Persistence in Chickens. **2018**, 8, 13381	19

625	N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model. **2018**, 26, 5169-5180	1
624	Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS. **2018**, 61, 8875-8894	22
623	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. **2018**, 61, 8374-8389	29
622	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. **2018**, 158, 781-800	40
621	Methyl-containing pharmaceuticals: Methylation in drug design. **2018**, 28, 3283-3289	48
620	Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates. **2018**, 15, 2656-2664	36
619	SeaBioTech: From Seabed to Test-Bed: Harvesting the Potential of Marine Biodiversity for Industrial Biotechnology. **2018**, 451-504	2
618	Synthesis and Molecular Drug Efficacy of Indoline-based Dihydroxy-thiocarbamides: Inflammation Regulatory Property Unveiled over COX-2 Inhibition, Molecular Docking, and Cytotoxicity Prospects. **2018**, 55, 1658-1668	2
617	Targeting G protein-coupled receptor signaling at the G protein level with a selective nanobody inhibitor. **2018**, 9, 1996	45
616	SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins. **2018**, 154, 233-252	14
615	The Impact of Novel Assessment Methodologies in Toxicology on Green Chemistry and Chemical Alternatives. **2018**, 161, 276-284	9
614	Confocal Raman Microscopy for in Situ Measurement of Phospholipid-Water Partitioning into Model Phospholipid Bilayers within Individual Chromatographic Particles. **2018**, 90, 7048-7055	6
613	Synthesis, Reactivity, Functionalization, and ADMET Properties of Silicon-Containing Nitrogen Heterocycles. **2018**, 140, 6668-6684	43
612	Methylglucosylation of aromatic amino and phenolic moieties of drug-like biosynthons by combinatorial biosynthesis. **2018**, 115, E4980-E4989	29
611	Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain. **2018**, 61, 6779-6800	20
610	Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. **2018**, 61, 6592-6608	30
609	Current Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical Assays. **2018**, 165, 4-5	4
608	Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-B Inducing Kinase. **2018**, 61, 6801-6813	25

607	Cyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals. **2018**, 10, 724-731	79
606	Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. **2018**, 10, 1705-1720	5
605	Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine HR ligands. **2018**, 26, 4034-4046	14
604	Current advances in drug discovery for Chagas disease. **2018**, 155, 824-838	49
603	Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities. **2018**, 9, 395	23
602	Bibliography. **2018**, 151-157	
601	Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions. **2018**, 19, 1133-1138	12
600	Determination of ligand efficiency indices in a group of 7H-purine-2,6-dione derivatives with psychotropic activity using micellar electrokinetic chromatography. **2018**, 39, 2446-2453	3
599	Computational Approaches to Develop Isoquinoline Based Antibiotics through DNA Gyrase Inhibition Mechanisms Unveiled through Antibacterial Evaluation and Molecular Docking. **2018**, 37, e1800048	10
598	Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. **2018**, 61, 7168-7188	14
597	Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. **2018**, 23,	19
596	Critical comparison of shake-flask, potentiometric and chromatographic methods for lipophilicity evaluation (log P) of neutral, acidic, basic, amphoteric, and zwitterionic drugs. **2018**, 122, 331-340	16
595	Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. **2018**, 16, 278-288	4
594	New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8. **2018**, 156, 587-597	7
593	□Amylase and □Glucosidase InhibitoryActivity of Tetradecanoic Acid (TDA) from Sargassum wightii with Relevance to Type 2 Diabetes Mellitus. **2018**, 8, 180-191	6
592	Challenges with multi-objective QSAR in drug discovery. **2018**, 13, 851-859	14
591	Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski's Rule of Five. **2018**, 549, 133-149	42
590	Recovering Actives in Multi-Antitarget and Target Design of Analogs of the Myosin II Inhibitor Blebbistatin. **2018**, 6, 179	

589	A perspective on multi-target drug discovery and design for complex diseases. **2018**, 7, 3	307
588	A confidence predictor for logD using conformal regression and a support-vector machine. **2018**, 10, 17	21
587	Molecular modelling and synthesis of spiroimidazolidine-2,4-diones with dual activities as hypoglycemic agents and selective inhibitors of aldose reductase. **2018**, 79, 131-144	10
586	High-Throughput Screening of Phytochemicals: Application of Computational Methods. **2018**, 165-192	0
585	Low Magnetic Field Induced Surface Enhanced Transient Spin-Trajectory Modulation of a Prototype Anticancer Drug Sanguinarine on a Single Domain Superparamagnetic Nanosurface. **2018**, 122, 20619-20631	1
584	Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery. **2018**, 23,	50
583	Accessing Polysubstituted Quinazolines via Nickel Catalyzed Acceptorless Dehydrogenative Coupling. **2018**, 83, 11154-11166	57
582	Visible-Light-Mediated Efficient Metal-Free Catalyst for Oxygenation of Tertiary Amines to Amides. **2018**, 8, 6659-6664	80
581	2,3-Dihydroquinazolin-4(1)-one as a privileged scaffold in drug design.. **2018**, 8, 20894-20921	49
580	Integrated Strategy for Lead Optimization Based on Fragment Growing: The Diversity-Oriented-Target-Focused-Synthesis Approach. **2018**, 61, 5719-5732	35
579	Synthesis, docking and anticancer activity of azo-linked hybrids of 1,3,4-thia-/oxadiazoles with cyclic imides. **2018**, 22, 827-840	6
578	Where Do Recent Small Molecule Clinical Development Candidates Come From?. **2018**, 61, 9442-9468	78
577	ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors. **2018**, 28, 2622-2626	10
576	Anti-cancer study and whey protein complexation of new lanthanum(III) complex with the aim of achieving bioactive anticancer metal-based drugs. **2019**, 37, 2072-2085	17
575	Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions. **2019**, 62, 1096-1115	50
574	Phenylthiazoles with nitrogenous side chain: An approach to overcome molecular obesity. **2019**, 182, 111593	8
573	Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors. **2019**, 59, 3782-3793	33
572	Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1,2)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropane Acid (AZD9898) as a New Treatment for Asthma. **2019**, 62, 7769-7787	0

571	Using Physicochemical Measurements to Influence Better Compound Design. **2019**, 24, 791-801	11
570	Innovations in Oral Therapies for Inflammatory Bowel Disease. **2019**, 79, 1321-1335	30
569	Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4). **2019**, 10, 1228-1233	19
568	Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. **2019**, 119, 10520-10594	243
567	Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery. **2019**, 2019, 5219-5229	17
566	C□N Cross-Coupling Reactions Under Mild Conditions Using Singlet Di-Radical Nickel(II)-Complexes as Catalyst: N-Arylation and Quinazoline Synthesis. **2019**, 361, 4342-4353	17
565	Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1). **2019**, 10, 1260-1265	4
564	Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. **2019**, 179, 608-622	10
563	Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1). **2019**, 62, 8996-9007	11
562	Rhodium(III)-Catalyzed C-H Activation: Ligand-Controlled Regioselective Synthesis of 4-Methyl-Substituted Dihydroisoquinolones. **2019**, 21, 5689-5693	18
561	The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis. **2019**, 107-123	
560	Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine. **2019**, 125-154	1
559	The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain. **2019**, 155-183	
558	Discovery and Development of Non-Covalent, Reversible Bruton□s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). **2019**, 239-266	1
557	Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. **2019**, 267-296	
556	Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection. **2019**, 297-322	
555	Preface. **2019**, xi-xiv	
554	A computational study targeting the mutated L321F of ERG11 gene in C.□albicans, associated with fluconazole resistance with bioactive compounds from Acacianilotica. **2019**, 29, 303-309	4

535	Pharmaceutical property interpretation and biological property study on Ethionamide using quantum spectroscopic and computational tools. **2019**, 13, 917-931	1
534	Synthetic Routes for Venetoclax at Different Stages of Development. **2019**, 1-25	
533	Chalcone derivatives targeting mitosis: synthesis, evaluation of antitumor activity and lipophilicity. **2019**, 184, 111752	16
532	Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. **2019**, 27-59	2
531	From Discovery to Market Readiness: The Research and Development of the Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib. **2019**, 61-83	1
530	Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis. **2019**, 185-238	
529	Discovery and Development of the First Antibody Antibiotic Conjugate Linker-Drug. **2019**, 85-105	2
528	Predicting protein-ligand binding affinity and correcting crystal structures with quantum mechanical calculations: lactate dehydrogenase A. **2019**, 10, 2218-2227	7
527	Synthesis, In Silico, and In Vitro Evaluation of Long Chain Alkyl Amides from 2-Amino-4-Quinolone Derivatives as Biofilm Inhibitors. **2019**, 24,	6
526	Enantioselective synthesis of (R)-2-cubylglycine including unprecedented rhodium mediated C-H insertion of cubane. **2019**, 17, 1067-1070	9
525	Cytotoxic Ru-p-cymene complexes of an anthraimidazoledione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation. **2019**, 48, 7187-7197	13
524	6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. **2019**, 62, 1793-1802	45
523	Dark Classics in Chemical Neuroscience: Tetrahydrocannabinol. **2019**, 10, 2160-2175	31
522	The CSD Drug Subset: The Changing Chemistry and Crystallography of Small Molecule Pharmaceuticals. **2019**, 108, 1655-1662	22
521	Orthogonal experimental preparation of Sanguis Draconis- Polyvinylpyrrolidone microfibers by electrospinning. **2019**, 30, 308-321	1
520	The nature of ligand efficiency. **2019**, 11, 8	28
519	Strategies to optimize drug half-life in lead candidate identification. **2019**, 14, 221-230	9
518	Mineralocorticoid Receptor Antagonists. **2019**, 109, 151-188	3

517	Predicting the Risks of Drug-Induced Liver Injury in Humans Utilizing Computational Modeling. **2019**, 259-278	
516	An overview on the synthetic and medicinal perspectives of indenopyrazoles. **2019**, 178, 1-12	8
515	The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor. **2019**, 355-387	1
514	Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors. **2019**, 27, 3383-3389	6
513	Fragment-based drug design of nature-inspired compounds. **2019**, 4,	2
512	Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. **2019**, 137, 104967	118
511	The Accordion Pill: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs. **2019**, 10, 433-442	6
510	Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. **2019**, 7, 26	3
509	Revealing Drug Self-Associations into Nano-Entities. **2019**, 4, 8919-8925	3
508	3-Arylindanones and related compounds as antiproliferative agents against colorectal cancer. **2019**, 94, 1694-1705	
507	Imidazole and Methoxybenzylamine Growth Inhibitors Reduce Persistence in Tomato Plant Tissues. **2019**, 82, 997-1006	4
506	Eigen Value ANalySis (EVANS) - A Tool to Address Pharmacodynamic, Pharmacokinetic and Toxicity Issues. **2019**, 4, 118-136	0
505	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. **2019**, 62, 6540-6560	13
504	Copper-catalyzed synthesis of 2-aminopyridylbenzoxazoles domino reactions of intermolecular -arylation and intramolecular -arylation.. **2019**, 9, 13414-13417	1
503	Offline preparative 2-D polar-copolymerized reversed-phase chromatography ‖zwitterionic hydrophilic interaction chromatography for effective purification of polar compounds from Caulis Polygoni Multiflori. **2019**, 1118-1119, 70-77	11
502	CFH, a Functional Group-Dependent Hydrogen-Bond Donor: Is It a More or Less Lipophilic Bioisostere of OH, SH, and CH?. **2019**, 62, 5628-5637	86
501	Nitroketene ,-acetals: synergistic building blocks for the synthesis of heterocycles.. **2019**, 9, 14477-14502	25
500	Cu and Au Complexes with Glycoconjugated Dithiocarbamato Ligands for Potential Applications in Targeted Chemotherapy. **2019**, 14, 1162-1172	11

499	High-throughput screening of the Plasmodium falciparum cGMP-dependent protein kinase identified a thiazole scaffold which kills erythrocytic and sexual stage parasites. **2019**, 9, 7005	25
498	An efficient microwave-promoted three-component synthesis of thiazolo[3,2-a]pyrimidines catalyzed by SiO2ZnBr2 and antimicrobial activity evaluation. **2019**, 55, 266-274	3
497	Cheminformatics techniques in antimalarial drug discovery and development from natural products 1: basic concepts. **2019**, 4,	1
496	Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. **2019**, 29, 1555-1564	127
495	Discovery of 2-phenoxyacetamides as inhibitors of the Wnt-depalmitoleating enzyme NOTUM from an X-ray fragment screen. **2019**, 10, 1361-1369	17
494	UPLC-HRMS and NMR applied in the evaluation of solid-phase extraction methods as a rational strategy of dereplication of Phyllanthus spp. aiming at the discovery of cytotoxic metabolites. **2019**, 1120, 51-61	5
493	Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents. **2019**, 174, 116-129	19
492	Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. **2019**, 62, 3428-3446	37
491	Characterization of Drug-like Chemical Space for Cytotoxic Marine Metabolites Using Multivariate Methods. **2019**, 4, 5402-5411	8
490	Beyond the Flavour: The Potential Druggability of Chemosensory G Protein-Coupled Receptors. **2019**, 20,	37
489	DFT and QSAR investigations of substituent effects in pyrazolooxazine derivatives: Activity prediction. **2019**, 18, 1950001	2
488	In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach. **2019**, 625-648	3
487	EASL Clinical Practice Guidelines: Drug-induced liver injury. **2019**, 70, 1222-1261	327
486	Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. **2019**, 11, 489-493	16
485	Properties of FDA-approved small molecule protein kinase inhibitors. **2019**, 144, 19-50	247
484	Structures and anticancer activity of chlorido platinum(II) saccharinate complexes with mono- and dialkylphenylphosphines. **2019**, 195, 39-50	14
483	Seleno-Michael Reaction of Stable Functionalised Alkyl Selenols: A Versatile Tool for the Synthesis of Acyclic and Cyclic Unsymmetrical Alkyl and Vinyl Selenides. **2019**, 361, 2337-2346	26
482	A combinatorial approach for the discovery of drug-like inhibitors of 15-lipoxygenase-1. **2019**, 174, 45-55	8

481	Synthesis of novel amides, characterization by spectrometric methods, cytotoxic activity and theoretical calculations. **2019**, 1191, 6-16	1
480	QSAR Modeling and Drug-Likeness Screening for Antioxidant Activity of Benzofuran Derivatives. **2019**, 1189, 307-314	11
479	Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease. **2019**, 62, 4325-4349	7
478	Metal-Free Photocatalysts for C-H Bond Oxygenation Reactions with Oxygen as the Oxidant. **2019**, 12, 2898-2910	58
477	Accelerated drug discovery by rapid candidate drug identification. **2019**, 24, 1237-1241	14
476	Biased Complement Diversity Selection for Effective Exploration of Chemical Space in Hit-Finding Campaigns. **2019**, 59, 1709-1714	4
475	Axially Chiral Cyclic Phosphoric Acid Enabled Enantioselective Sequential Additions. **2019**, 21, 2498-2503	14
474	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. **2019**, 142, 151-168	100
473	Synthesis of quinazolin-4(1H)-ones via amination and annulation of amidines and benzamides. **2019**, 17, 2356-2360	6
472	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. **2019**, 15, 62-69	52
471	Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors. **2019**, 62, 3068-3087	10
470	Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations. **2019**, 86, 410-419	11
469	Mind and machine in drug design. **2019**, 1, 128-130	30
468	Drug-Induced Liver Disease: Mechanism and Diagnosis. **2019**, 715-728	1
467	Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90). **2019**, 20,	11
466	Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases. **2019**, 62, 11359-11382	35
465	Carboranylanilinoquinazoline EGFR-inhibitors: toward‘lead-to-candidate’ stage in the drug-development pipeline. **2019**, 11, 2273-2285	10
464	(3 + 1) Annulation/Rearrangement Cascade of -Cyclic Azomethine Imines and 3-Chlorooxindoles: Construction of Hexahydroindeno[2,1-]pyrazole Spirooxindole Frameworks. **2019**, 21, 10052-10056	9

463	Revisiting the structure of a synthetic somatostatin analogue for peptide drug design. **2019**, 75, 611-620	7
462	Synergistic catalysis on Fe-N sites and Fe nanoparticles for efficient synthesis of quinolines and quinazolinones oxidative coupling of amines and aldehydes. **2019**, 10, 10283-10289	50
461	Pharmacological and SAR analysis of the LINS01 compounds at the human histamine H , H , and H receptors. **2019**, 93, 89-95	4
460	Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals. **2019**, 24, 1-24	17
459	Synthesis approach and biological activity evaluation of a series of 1,3,2-oxazaphosphole-2-oxides against inflammation and nociception. **2019**, 150, 283-294	0
458	Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors. **2019**, 29, 406-412	2
457	Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors. **2019**, 27, 644-654	10
456	Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects. **2019**, 29, 73-77	8
455	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. **2019**, 162, 378-395	32
454	Optimization of a 1,3,4-oxadiazole series for inhibition of Ca/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain. **2019**, 162, 568-585	9
453	Analysis of solvent-exposed and buried co-crystallized ligands: a case study to support the design of novel protein-protein interaction inhibitors. **2019**, 24, 551-559	11
452	Fragment-to-Lead Medicinal Chemistry Publications in 2017. **2019**, 62, 3857-3872	27
451	Synthesis of New Potential Lipophilic Co-Drugs of 2-Chloro-2'-deoxyadenosine (Cladribine, 2-CdA, Mavenclad , Leustatin) and 6-Azauridine (z U) with Valproic Acid. **2019**, 16, e1800497	1
450	Visualize Embryogenesis and Cell Fate Using Fluorescent Probes with Aggregation-Induced Emission. **2019**, 11, 3737-3744	9
449	In vitro and in silico inhibition properties of fucoidan against amylase and D-glucosidase with relevance to type 2 diabetes mellitus. **2019**, 209, 350-355	55
448	Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. **2019**, 161, 479-492	11
447	Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors. **2019**, 161, 533-542	5
446	Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists. **2019**, 162, 631-649	8

445	Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond - Part 2. **2019**, 29, 674-680	3
444	Population Balance Model for Simulation of the Supersaturation-Precipitation Behavior of Drugs in Supersaturable Solid Forms. **2019**, 108, 260-267	5
443	Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1. **2019**, 29, 668-673	3
442	Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na) 1.7 with Potent Analgesic Activity. **2019**, 62, 908-927	20
441	Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. **2019**, 62, 247-265	27
440	Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs. **2019**, 31, 595-601	17
439	Dynamic structure based pharmacophore modeling of the Acetylcholinesterase reveals several potential inhibitors. **2019**, 37, 1800-1812	26
438	Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery. **2020**, 50, 270-279	8
437	Evaluation of the inhibitory effect of caffeic acid and gallic acid on tetR and tetM efflux pumps mediating tetracycline resistance in Streptococcus sp., using computational approach. **2020**, 32, 904-909	3
436	An Overview of Machine Learning and Big Data for Drug Toxicity Evaluation. **2020**, 33, 20-37	49
435	Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability. **2020**, 109, 161-168	8
434	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. **2020**, 33, 154-161	5
433	Modifying the lipophilic part of phenylthiazole antibiotics to control their drug-likeness. **2020**, 185, 111830	11
432	Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies. **2020**, 63, 6251-6275	7
431	Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent Notum inhibitors. **2020**, 30, 126751	9
430	Application of Negative Design To Design a More Desirable Virtual Screening Library. **2020**, 63, 4411-4429	14
429	Influence of polymeric excipients on the solubility of aspirin: Experimental measurement and model prediction. **2020**, 508, 112450	5
428	Fragment-to-Lead Medicinal Chemistry Publications in 2018. **2020**, 63, 4430-4444	37

427	Gemini basic ionic liquid as bi-functional catalyst for the synthesis of 2,3-dihydroquinazolin-4(1H)-ones at room temperature. **2020**, 61, 151587	13
426	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. **2020**, 152, 104609	244
425	Is there enough focus on lipophilicity in drug discovery?. **2020**, 15, 261-263	19
424	Thermodynamic profiling for fragment-based lead discovery and optimization. **2020**, 15, 117-129	2
423	An in vitro toolbox to accelerate anti-malarial drug discovery and development. **2020**, 19, 1	72
422	Alkyne Linchpin Strategy for Drug:Pharmacophore Conjugation: Experimental and Computational Realization of a -Selective Inverse Sonogashira Coupling. **2020**, 142, 3762-3774	56
421	Docking Finds GPCR Ligands in Dark Chemical Matter. **2020**, 63, 613-620	11
420	Highly Dispersed Single-Phase Ni2P Nanoparticles on N,P-Codoped Porous Carbon for Efficient Synthesis of N-Heterocycles. **2020**, 8, 267-277	24
419	The blood-brain barrier: Physiology and strategies for drug delivery. **2020**, 165-166, 1-14	104
418	Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents. **2020**, 94, 103474	10
417	Application of Hammett equation to hydrogen bond interactions of benzoic acid in chloroform/water system and explanation for non-linear Hammett relation to partition coefficients for the same system. **2020**, 1190, 113024	2
416	Chemoinformatic Approach: The Case of Natural Products of Panama. **2020**,	2
415	. **2020**,	0
414	3-Hetarylisocoumarins in the synthesis of 1-functionalized 3-hetarylisoquinolines. **2020**, 56, 1021-1029	1
413	preADMET analysis and clinical aspects of dogs treated with the Organotellurium compound RF07: A possible control for canine visceral leishmaniasis?. **2020**, 80, 103470	12
412	Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7). **2020**, 30, 127510	5
411	A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?. **2020**, 109, 3248-3261	8
410	Cyanobacterial metabolites as promising drug leads against the M and PL of SARS-CoV-2: an analysis. **2021**, 39, 6218-6230	24

409	Synergistic potential of Citrus aurantium L. essential oil with antibiotics against Candida albicans. **2020**, 262, 113135	26
408	Novel phenethylimidazolium based ionic liquids: Design, microwave synthesis, in-silico, modeling and biological evaluation studies. **2020**, 315, 113778	10
407	Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone. **2020**, 25, 1846-1854	5
406	Pharmacokinetics (ADME). **2020**, 133-224	
405	Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants. **2020**, 8, e00603	7
404	Indole Propionic Acid, an Unusual Antibiotic Produced by the Gut Microbiota, With Anti-inflammatory and Antioxidant Properties. **2020**, 11, 575586	17
403	Fragment-to-Lead Medicinal Chemistry Publications in 2019. **2020**, 63, 15494-15507	18
402	EST64454: a Highly Soluble Receptor Antagonist Clinical Candidate for Pain Management. **2020**, 63, 14979-14988	3
401	Combinatorial Biosynthesis of Sulfated Benzenediol Lactones with a Phenolic Sulfotransferase from Fusarium graminearum PH-1. **2020**, 5,	4
400	Highly Potent and Selective -Aryl Oxamic Acid-Based Inhibitors for Protein Tyrosine Phosphatase B. **2020**, 63, 9212-9227	9
399	A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1. **2020**, 11, 1704-1710	2
398	Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists. **2020**, 63, 9705-9730	4
397	Harnessing emerging paradigms in chemical engineering to accelerate the development of pharmaceutical products. **2020**, 98, 2294-2300	0
396	Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity. **2020**, 63, 9464-9483	7
395	Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses. **2020**, 103, 104133	20
394	Synthesis of Degraded Limonoid Analogs as New Antibacterial Scaffolds against. **2020**, 9,	0
393	Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry. **2020**, 63, 14243-14275	69
392	Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). **2020**, 63, 11639-11662	4

391	Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'. **2020**, 30, 127533	1
390	A [3 + 2] cycloaddition/C-arylation of isatin ,'-cyclic azomethine imine 1,3-dipole with arynes.. **2020**, 10, 30620-30623	6
389	Diversity-Oriented Synthesis of Thiazolidine-2-imines via Microwave-Assisted One-Pot, Telescopic Approach and Its Interaction with Biomacromolecules. **2020**, 22, 630-640	5
388	Evaluation of DNA Binding and Topoisomerase I Inhibitory Activities of 16Decarbomethoxydihydrovoacamine from Tabernaemontana corymbosa. **2020**, 5, 14839-14843	1
387	Mono-Alkylated Ligands Based on Pyrazole and Triazole Derivatives Tested Against . sp. : Synthesis, Characterization, DFT, and Phytase Binding Site Identification Using Blind Docking/Virtual Screening for Potent Fophy Inhibitors. **2020**, 8, 559262	4
386	Inhibitors of dipeptidyl peptidase-4 as therapeutic agents for individuals with type 2 diabetes: a 25-year journey. **2020**, 37, 1230-1233	5
385	(E)-2-(2-Allylidenehydrazinyl)thiazole derivatives: Design, green synthesis, in silico and in vitro antimycobacterial and radical scavenging studies. **2020**, 353, e2000003	7
384	Design, synthesis and antiproliferative activity of new amine, amino acid and dipeptide-coupled benzamides as potential sigma-1 receptor. **2020**, 17, 2515-2532	10
383	Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say?. **2020**, 26, 120	18
382	Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors. **2020**, 11, 1213-1220	10
381	Theoretical studies and NMR assay of coumarins and neoflavanones derivatives as potential inhibitors of acetylcholinesterase. **2020**, 87, 107293	1
380	Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects. **2020**, 201, 112456	3
379	Base-promoted Lewis acid catalyzed synthesis of quinazoline derivatives. **2020**,	5
378	Serendipitous Synthesis of Pyridoquinazolinones an Oxidative C-C Bond Cleavage. **2020**, 85, 8102-8110	10
377	Synthesis, characterization and catalytic application of tributyl(carboxymethyl)phosphonium bromotrichloroferrate as a new magnetic ionic liquid for the preparation of 2,3-dihydroquinazolin-4(1H)-ones and 4H-pyrimidobenzothiazoles. **2020**, 46, 3945-3960	4
376	Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a Opioid Receptor Agonist/Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. **2020**, 63, 7663-7694	7
375	Stabilizing Inactive Conformations of MALT1 as an Effective Approach to Inhibit Its Protease Activity. **2020**, 3, 2000078	2
374	Didactic approach recounting advances and limitations in novel glutathione and cysteine detection (reduced GSH probe) with mixed coumarin, aldehyde, and phenyl-selenium chemistry. **2020**, 640, 267-289	4

373	Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation. **2020**, 25,	25
372	Combining Cloud-Based Free-Energy Calculations, Synthetically Aware Enumerations, and Goal-Directed Generative Machine Learning for Rapid Large-Scale Chemical Exploration and Optimization. **2020**, 60, 4311-4325	15
371	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. **2020**, 63, 8088-8113	7
370	Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. **2020**, 63, 7163-7185	17
369	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. **2020**, 63, 7369-7391	11
368	Systems Pharmacology-Dissection of the Molecular Mechanisms of Dragon's Blood in Improving Ischemic Stroke Prognosis. **2020**, 2020, 4858201	1
367	Computational methods and tools for sustainable and green approaches in drug discovery. **2020**, 965-988	1
366	Synthetic approaches toward small molecule libraries. **2020**, 1-34	1
365	Synthetic and antimicrobial studies of N-substituted-pyrazoline-based new bisheterocycles. **2020**, 57, 2024-2036	2
364	Benzimidazoquinazolines as new potent anti-TB chemotypes: Design, synthesis, and biological evaluation. **2020**, 99, 103774	17
363	Molecular Iodine-Promoted [3 + 2] Oxidative Cyclization for the Synthesis of Heteroarene-Fused [1,2,4] Thiadiazoles/Selenadiazoles. **2020**, 85, 5570-5579	5
362	Identification of novel and selective agonists for ABA receptor PYL3. **2020**, 154, 387-395	10
361	Discovery of 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4: Biological evaluation and docking studies. **2020**, 353, e2000097	5
360	p-TSA.HO mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer. **2020**, 102, 104046	9
359	Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp character and an exquisite selectivity profile. **2020**, 30, 127405	4
358	Design of iodinated radioligands for SPECT imaging of central human 5-HTR using a ligand lipophilicity efficiency approach. **2020**, 96, 103582	1
357	Striking essential oil: tapping into a largely unexplored source for drug discovery. **2020**, 10, 2867	11
356	Cutaneous Adverse Events Caused by Sulfonamide-Containing Drugs: Reality or Perception?. **2020**, 63, 7447-7457	7

355	A Novel Systematic Approach for Selection of Prodrugs Designed to Improve Oral Absorption. **2020**, 109, 1736-1746	2
354	Electronic complementarity permits hindered butenolide heterodimerization and discovery of novel cGAS/STING pathway antagonists. **2020**, 12, 310-317	16
353	Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1. **2020**, 5, 822-831	3
352	Lipophilic Metabolic Efficiency (LipMetE) and Drug Efficiency Indices to Explore the Metabolic Properties of the Substrates of Selected Cytochrome P450 Isoforms. **2020**, 5, 179-188	4
351	Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics. **2020**, 26, 7219-7225	10
350	Combining Structural, Thermodynamic, and Kinetic Information to Drive Hit-to-Lead Progression. **2020**, 99-124	1
349	Prediction of octanol-water partition coefficients for the SAMPL6-[Formula: see text] molecules using molecular dynamics simulations with OPLS-AA, AMBER and CHARMM force fields. **2020**, 34, 543-560	18
348	Vascular Epiphytic Medicinal Plants as Sources of Therapeutic Agents: Their Ethnopharmacological Uses, Chemical Composition, and Biological Activities. **2020**, 10,	18
347	Utility of Physicochemical Properties for the Prediction of Toxicological Outcomes: Takeda Perspective. **2020**, 11, 203-209	8
346	The use of Sulfonamide Derivatives in the Treatment of Trypanosomatid Parasites including Trypanosoma cruzi, Trypanosoma brucei, and Leishmania ssp. **2020**, 16, 24-38	3
345	Xanthones, A Promising Anti-Inflammatory Scaffold: Structure, Activity, and Drug Likeness Analysis. **2020**, 25,	35
344	The discovery, design and synthesis of potent agonists of adenylyl cyclase type 2 by virtual screening combining biological evaluation. **2020**, 191, 112115	4
343	Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. **2020**, 5, e10163	4
342	A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. **2020**, 25,	262
341	Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. **2020**, 63, 8025-8042	10
340	Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. **2020**, 160, 121-140	41
339	Systematically altering the lipophilicity of rhenium(I) tricarbonyl anticancer agents to tune the rate at which they induce cell death. **2020**, 49, 16062-16066	10
338	Data science-driven analyses of drugs inducing hypertension as an adverse effect. **2021**, 25, 801-810	1

337	Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening. **2021**, 26, 113-121	2
336	Novel potent (dihydro)benzofuranyl piperazines as human histamine receptor ligands - Functional characterization and modeling studies on H and H receptors. **2021**, 30, 115924	3
335	Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents. **2021**, 107, 104538	12
334	Switchable and efficient conversion of 2-amido-aryl oxazolines to quinazolin-4(3H)-ones and N-(2-chloroethyl)benzamides. **2021**, 8, 584-590	2
333	Comprehensive two-dimensional liquid chromatography as a biomimetic screening platform for pharmacokinetic profiling of compound libraries in early drug development. **2021**, 1142, 157-168	2
332	ReSCoSS: a flexible quantum chemistry workflow identifying relevant solution conformers of drug-like molecules. **2021**, 35, 399-415	6
331	Lewis-acid-promoted cyclization reaction: synthesis of N3-chloroethyl and N3-thiocyanatoethyl quinazolinones. **2021**, 45, 9315-9319	0
330	Discovery of a Novel and Brain-Penetrant -GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization. **2021**, 64, 1103-1115	0
329	A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase. **2021**, 27, 35	0
328	Holistic Assessment of Compound PropertiesIn Vitro to In Vivo Pharmacology. **2021**,	
327	CHAPTER 3:Optimisation of Passive Permeability for Oral Absorption. **2021**, 36-61	
326	Put a ring on it: application of small aliphatic rings in medicinal chemistry. **2021**, 12, 448-471	43
325	8-cyanobenzothiazinone analogs with potent antitubercular activity. **2021**, 30, 1-10	3
324	Novel Tandem Three Consecutive Reactions: Aza-Wittig, Imine Condensation and Electrophilic Aromatic Substitution Strategy to Indolizine Synthesis. **2021**, 11, 55-71	
323	Imidazopyridine-Based 5-HT Receptor Neutral Antagonists: Impact of -Benzyl and -Phenylsulfonyl Fragments on Different Receptor Conformational States. **2021**, 64, 1180-1196	9
322	Structure-activity relationship of ipglycermide binding to phosphoglycerate mutases. **2021**, 296, 100628	0
321	Modified biopolymer-based systems for drug delivery to the brain. **2021**, 571-611	2
320	Analysis of physicochemical properties of protein-protein interaction modulators suggests stronger alignment with the "rule of five". **2021**, 12, 1731-1749	2

319	In silico validation and ADMET analysis for the best lead molecules. **2021**, 133-176	0
318	Pharmaceutical profiling. **2021**, 155-167	
317	Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay. **2021**, 11, 1413	6
316	Synthetic applications of □difluoroarylacetic acids and salts via decarboxylative functionalization. **2021**, 8, 5516-5530	4
315	Physicochemical Profiling and Comparison of Research Antiplasmodials and Advanced Stage Antimalarials with Oral Drugs. **2021**, 6, 6424-6437	0
314	ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors. **2021**, 33, 127721	3
313	Metabolite profile of Nectandra oppositifolia Nees & Mart. and assessment of antitrypanosomal activity of bioactive compounds through efficiency analyses. **2021**, 16, e0247334	1
312	Recent investigations into synthesis and pharmacological activities of phenoxy acetamide and its derivatives (chalcone, indole and quinoline) as possible therapeutic candidates. **2021**, 18, 1839	5
311	Synthesis and biological evaluation of novel withangulatin A derivatives as potential anticancer agents. **2021**, 108, 104690	0
310	Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. **2021**, 64, 3658-3676	6
309	Ligand efficiency indices for effective drug discovery: a unifying vector formulation. **2021**, 16, 763-775	0
308	Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity. **2021**, 187, 109123	6
307	Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy. **2021**, 4, 953-965	1
306	Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach. **2021**, 34, 116034	1
305	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. **2021**, 165, 105463	107
304	Recent Experimental Developments in Studying Passive Membrane Transport of Drug Molecules. **2021**, 18, 2122-2141	5
303	Structure-Based Drug Design for G Protein-Coupled Receptors. 1-59	
302	Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding. **2021**, 38, 127857	3

301	New Succinimides with Potent Anticancer Activity: Synthesis, Activation of Stress Signaling Pathways and Characterization of Apoptosis in Leukemia and Cervical Cancer Cells. **2021**, 22,	1
300	The Bisindole Alkaloids Angustilongines M and A from Induce Mitochondrial Apoptosis and G0/G1 Cell Cycle Arrest in HT-29 Cells through Promotion of Tubulin Polymerization. **2021**, 84, 1524-1533	1
299	What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. **2021**, 64, 4410-4429	4
298	Actives from MMV Open Access Boxes? A suggested way forward. **2021**, 17, e1009384	3
297	Covalent Organic Frameworks toward Diverse Photocatalytic Aerobic Oxidations. **2021**, 27, 7738-7744	5
296	Recent Advances in Chemistry Technologies and Applications to Medicinal Chemistry. 1-78	
295	Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres. **2021**, 64, 7231-7240	6
294	Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators. **2021**, 64, 7296-7311	10
293	Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies. **2021**, 64, 7210-7230	9
292	Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives. **2021**, 41, 116208	1
291	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer□ Disease. **2021**, 11, 4305	5
290	Apigenin and Structurally Related Flavonoids Allosterically Potentiate the Function of Human □7-Nicotinic Acetylcholine Receptors Expressed in SH-EP1 Cells. **2021**, 10,	1
289	Molecular Docking and Dynamics Simulation Study of □Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors. **2021**, 10,	11
288	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. **2021**, 16, 1091-1103	1
287	Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9. **2021**, 64, 9279-9301	2
286	Computational screening of phytochemicals to discover potent inhibitors against chinkungunya virus. **2021**, 34, 515-527	1
285	Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review. **2021**,	1
284	Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors. **2021**, 12, 1108-1115	1

283	A new probe with high selectivity and sensitivity for detecting copper ions in traditional Chinese medicine and water sample. **2021**, 128, 108563		2
282	Semisynthetic Triazoles as an Approach in the Discovery of Novel Lead Compounds. **2021**, 25, 1097-1179		
281	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. **2021**, 168, 105579		13
280	Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: In vitro, in vivo, and in silico integrated approaches. **2021**, 111, 104877		9
279	Identification and validation of selective deubiquitinase inhibitors. **2021**,		5
278	Advances and Limitations of Antibody Drug Conjugates for Cancer. **2021**, 9,		16
277	In silico investigations on curcuminoids from Curcuma longa as positive regulators of the Wnt/catenin signaling pathway in wound healing. **2021**, 22,		1
276	Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. **2021**, 219, 113417		3
275	Prediction of n-octanol/water partition coefficients and acidity constants (pK) in the SAMPL7 blind challenge with the IEFPCM-MST model. **2021**, 35, 803-811		1
274	GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. **2021**, 64, 11841-11856		18
273	Ligand binding at the protein-lipid interface: strategic considerations for drug design. *Nature Reviews Drug Discovery*, **2021**, 20, 710-722	64.1	15
272	The PROTACtable genome. *Nature Reviews Drug Discovery*, **2021**, 20, 789-797	64.1	20
271	Thiazole, triazole, thio- and semicarbazone derivatives - Promising moieties for drug development for the treatment of tuberculosis. **2021**, 1, 100002		2
270	Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2-benzo[][1,4]oxazin-6-yl Moiety. **2021**, 64, 11014-11044		5
269	Chemical and Structural Strategies to Selectively Target mTOR Kinase. **2021**, 16, 2744-2759		5
268	Active Ingredients from Steam Distilled Essential Oil Inhibit PC-3 Prostate Cancer Cell Growth via Direct Action and Indirect Immune Cells Conditioned Media In Vitro. **2021**, 43, 996-1018		0
267	Amino-Substituted 3-Aryl- and 3-Heteroarylquinolines as Potential Antileishmanial Agents. **2021**, 64, 12152-12162		0
266	Ailanthoidol, a Neolignan, Suppresses TGF--Induced HepG2 Hepatoblastoma Cell Progression. **2021**, 9,		0

265	Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimer's Disease: C-Synthesis and Proof of Concept. **2021**,	3
264	Acetylation turns leucine into a drug by membrane transporter switching. **2021**, 11, 15812	0
263	Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability. **2021**, 64, 12705-12722	3
262	Non-Extensive Fragmentation of Natural Products and Pharmacophore-Based Virtual Screening as a Practical Approach to Identify Novel Promising Chemical Scaffolds. **2021**, 9, 700802	0
261	Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders. **2021**, 64, 11774-11797	7
260	Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression. **2021**, 64, 12200-12227	4
259	Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ()-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3-1,2,4-triazol-3-one, by Fragment-Based Drug Design. **2021**, 64, 12893-12902	4
258	Accelerating antibiotic discovery through artificial intelligence. **2021**, 4, 1050	9
257	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. **2021**, 64, 13604-13621	1
256	Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}--methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. **2021**, 64, 14498-14512	8
255	Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. **2021**, 16, 3326-3341	
254	Design, synthesis and biological evaluation of novel thiohydantoin derivatives as antiproliferative agents: A combined experimental and theoretical assessments. **2021**, 1249, 131574	5
253	Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design. **2021**, 64, 14046-14128	20
252	Emerging building blocks for medicinal chemistry: recent synthetic advances.	2
251	Integrating Network Pharmacology and RT-qPCR Analysis to Investigate the Mechanisms Underlying ZeXie Decoction-Mediated Treatment of Non-alcoholic Fatty Liver Disease. **2021**, 12, 722016	2
250	Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain.. **2022**, 12, 1377-1389	1
249	An efficient drug compound analysis model based on Mutual Spectral Scaling Feature Selection using Spectral Deep Feature Classification for Drug recommendation from health care. **2021**, 100009	
248	Optimization of an Imidazo[1,2-]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with Efficacy. **2021**, 64, 13524-13539	1

247	Anticancer properties of bisaminoquinolines with modified linkers. **2021**, 49, 128272	0
246	Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. **2021**, 223, 113678	3
245	Discovery of tetrahydro-β-carboline- and indole-based derivatives as promising phosphodiesterase-4 inhibitors: Synthesis, biological evaluation, and molecular modeling studies. **2022**, 1248, 131491	0
244	A targeted covalent small molecule inhibitor of HIV-1 fusion. **2021**, 57, 4528-4531	1
243	Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Growth. **2021**, 6, 2284-2311	8
242	Recent developments and perspectives in the copper-catalyzed multicomponent synthesis of heterocycles.. **2021**, 11, 3452-3469	19
241	The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer.. **2020**, 11, 899-908	9
240	CHAPTER 2:Tactics to Improve Solubility. **2021**, 16-35	
239	Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. **2021**, 26,	12
238	Selective C(sp3)–H activation of simple alkanes: visible light-induced metal-free synthesis of phenanthridines with H2O2 as a sustainable oxidant. **2021**, 23, 6926-6930	10
237	Chemogenomics for drug discovery: clinical molecules from open access chemical probes. **2021**, 2, 759-795	2
236	Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes. **2021**, 11, 207	6
235	Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies. 1	1
234	Activity at Cardiovascular Ion Channels: A Key Issue for Drug Discovery. 83-109	1
233	DEVELOPMENT AND APPLICATIONS OF GLOBAL ADMET MODELS. 245-265	3
232	Attrition in Drug Discovery and Development. 5-45	2
231	What Does an HTS File of the Future Look Like?. 275-304	2
230	Generating a High-Quality Compound Collection. 9-21	3

229	Functional Cardiac Safety Evaluation of Novel Therapeutics. 199-234	1
228	QM Calculations in ADMET Prediction. **2020**, 2114, 285-305	4
227	Cell-Based Screening in Antibacterial Discovery. **2012**, 901-929	6
226	Curation of inhibitor-target data: process and impact on pathway analysis. **2009**, 563, 51-62	3
225	Database systems for knowledge-based discovery. **2009**, 575, 159-72	18
224	Chemical Structure-Based and Toxicogenomic Models. **2015**, 13-34	2
223	QSAR/QSPR Modeling in the Design of Drug Candidates with Balanced Pharmacodynamic and Pharmacokinetic Properties. **2017**, 339-384	2
222	Iatrogenic QT Prolongation. **2010**, 365-402	2
221	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. **2017**, 553-627	0
220	Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinase. **2020**, 194, 105494	35
219	CHAPTER 4:Current Status and Future Direction of Fragment-Based Drug Discovery: A Computational Chemistry Perspective. **2015**, 73-100	2
218	CHAPTER 5:Fragment Screening of G Protein-Coupled Receptors. **2015**, 101-125	1
217	Chapter 8:The Discovery of the Long-acting PDE5 Inhibitor PF-489791 for the Treatment of Pulmonary Hypertension. **2010**, 166-182	2
216	Ruthenium-initiated polymerization of lactide: a route to remarkable cellular uptake for photodynamic therapy of cancer. **2020**, 11, 2657-2663	19
215	Structure based virtual screening identifies small molecule effectors for the sialoglycan binding protein Hsa. **2020**, 477, 3695-3707	4
214	Fragments: where are we now?. **2020**, 48, 271-280	16
213	Therapeutics-how to treat phase separation-associated diseases. **2020**, 4, 307-318	24
212	Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes.	11

211	Advancing the activity cliff concept, part II. **2014**, 3, 75	23
210	Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key. **2013**, 8, e65894	101
209	Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins). **2014**, 9, e97438	33
208	Exploring the binding sites and binding mechanism for hydrotrope encapsulated griseofulvin drug on tubulin protein. **2018**, 13, e0190209	3
207	Targeting prolyl tripeptidyl peptidase from Porphyromonas gingivalis with the bioactive compounds from Rosmarinus officinalis. **2019**, 13, 197-203	1
206	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. **2017**, 8, 57246-57264	8
205	A newly identified berberine derivative induces cancer cell senescence by stabilizing endogenous G-quadruplexes and sparking a DNA damage response at the telomere region. **2015**, 6, 35625-35	26
204	A Recent Look into Natural Products that have Potential to Inhibit Cholinesterases and Monoamine Oxidase B: Update for 2010-2019. **2020**, 23, 862-876	2
203	Applications of in Silico Methods for Design and Development of Drugs Targeting Protein-Protein Interactions. **2019**, 19, 534-554	5
202	Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells. **2021**, 17, 40-59	4
201	Thrombolytic Activity, Drug Likeness Property and ADME/T Analysis of Isolated Phytochemicals from Ginger (<i>Zingiber officinale</i>) Using <i>In Silico</i> Approaches. **2019**, 08, 29-43	8
200	The Molecular Modeling of Novel Inhibitors of Protein Tyrosine Phosphatase 1B Based on Catechol by MD and MM-GB (PB)/SA Calculations. **2014**, 35, 1769-1776	3
199	Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. **2021**,	40
198	Electro-oxidative CH amination of heteroarenes with aniline derivatives via radical radical cross coupling.	3
197	Strategies to apply 3Rs in preclinical testing. **2021**, 9, e00863	4
196	Type 2 Diabetes Mellitus Mediation by the Disruptive Activity of Environmental Toxicants on Sex Hormone Receptors: In Silico Evaluation. **2021**, 9,	1
195	screening, SAR and kinetic studies of naturally occurring flavonoids against SARS CoV-2 main protease.. **2022**, 15, 103473	0
194	Immobilized beta-adrenergic receptor: A powerful chromatographic platform for drug discovery and evaluation of drug-like property for natural products. **2021**, 1659, 462635	1

193	Trisubstituted 1,3,5-Triazines: The First Ligands of the sY12-Binding Pocket on Chemokine CXCL12. **2021**, 12, 1773-1782	1
192	Drug-like Properties and Fraction Lipophilicity Index as a combined metric.. **2021**, 9, 177-190	1
191	Evaluation of a new series of pyrazole derivatives as a potent epidermal growth factor receptor inhibitory activity: QSAR modeling using quantum-chemical descriptors. **2021**, 42, 2306-2320	0
190	Next generation Glucose-1-phosphate thymidylyltransferase (RmlA) inhibitors: An extended SAR study to direct future design. **2021**, 50, 116477	0
189	Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with Efficacy against MRSA. **2021**, 64, 15214-15249	3
188	Ion Channels. 1	1
187	Chapter 12. A Case History on the Challenges of Central Nervous System and Dual Pharmacology Drug Discovery. **2010**, 267-286	1
186	Chapter 9:From HTS to Market: the Discovery and Development of Maraviroc, a CCR5 Antagonist for the Treatment of HIV. **2010**, 183-214	
185	Development of Agonists and Antagonists for Melatonin Receptors. **2014**, 97-116	
184	Clinical Aspects of Hepatitis C Virus Infection. 241-264	
183	Medicinal Chemistry Strategies to Prevent Compound Attrition. 215-228	
182	Inhibition Docking Simulation of Zerumbone, Gingerglycolipid B, and Curzerenone Compound of Zingiber zerumbet from Timor Island Against MurA Enzyme. **2016**, 279-288	2
181	Design of Favorable Compound Libraries for Biologists. **2018**, 76, 1102-1109	
180	. **2019**,	
179	Lead Optimization in the Drug Discovery Process. **2019**, 62-79	0
178	Synthesis of Some Aryl Ketoxime Derivatives with their in vitro Anti-microbial and Cytotoxic Activity. 001-006	0
177	Synthetic Studies of Vonoprazan Fumarate, a Novel Potassium-Competitive Acid Blocker (P-CAB). **2019**, 77, 254-261	
176	Structure based virtual screening identifies novel competitive inhibitors for the sialoglycan binding protein Hsa.	

175	Development of Composition and Technologies of Dental Gel of Meloxicam. **2020**, 8, 88-93	
174	Discovery of : an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction. **2021**, 64, 16213-16241	3
173	Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor Inverse Agonist. **2021**, 64, 16106-16131	2
172	Prospects for Discovering the Secondary Metabolites of Sensu Lato by the Integrated Strategy. **2021**, 17, 97-120	2
171	Multi-objective optimization methods in novel drug design. **2021**, 16, 647-658	4
170	In Silico Investigations on Curcuminoids from Curcuma longa as Positive Regulators of Wnt/catenin Signaling Pathway in Wound Healing.	
169	Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. **2021**,	3
168	Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints. **2022**, 2390, 61-101	1
167	Acetylation of L-leucine switches its carrier from the L-amino acid transporter (LAT) to organic anion transporters (OAT).	1
166	Ring Size as an Independent Variable in Cyclooligomeric Depsipeptide Antiarrhythmic Activity.. **2021**, 12, 1942-1947	0
165	Relative Binding Free-Energy Calculations at Lipid-Exposed Sites: Deciphering Hot Spots. **2021**,	0
164	Combined Pharmacophore and Grid-Independent Molecular Descriptors (GRIND) Analysis to Probe 3D Features of Inositol 1,4,5-Trisphosphate Receptor (IPR) Inhibitors in Cancer. **2021**, 22,	2
163	Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor inverse agonist.. **2021**, 119, 105483	1
162	Gold(I) Complexes with P-Donor Ligands and Their Biological Evaluation. **2021**, 9, 2100	
161	Molecular target prediction and docking of anti-thrombosis compounds and its activation on tissue-plasminogen activator to treat stroke. **2021**, 34, 101732	1
160	Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds.. **2021**, 9,	3
159	Recent Trends for Drug Development for the treatment of Adenocarcinoma breast cancer: Thiazole, Triazole, and Thiosemicarbazone Analogues as Efficient Scaffolds. **2021**,	0
158	Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor inverse agonists.. **2021**, 229, 114065	1

157	Polypharmacology: The science of multi-targeting molecules.. **2022**, 176, 106055	8
156	Advances in structure-based virtual screening for drug discovery. **2022**, 387-404	
155	2-Aminopyridine - an unsung hero in drug discovery.. **2021**,	3
154	Synthesis of Substituted Pyrano[3,4- b]Quinolines by Silver-Catalyzed Regioselective Intramolecular Cyclization of 3-Alkynylquinoline Aldehydes.	
153	Natural product drug discovery in the artificial intelligence era.. **2022**, 13, 1526-1546	11
152	Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5MTA Complex for the Treatment of -Deleted Cancers.. **2022**,	7
151	Directing Crystallization Outcomes of Conformationally Flexible Molecules: Polymorphs, Solvates, and Desolvation Pathways of Fluconazole.. **2022**,	0
150	Screening the Efficacy of Melatonin on Neurodegeneration Mediated by Endoplasmic Reticulum Stress, Inflammation, and Oxidative Damage.. **2022**, 194, 1105	
149	Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update.. **2021**, 106037	22
148	Synthesis of aminoethyl substituted piperidine derivatives as receptor ligands with antiproliferative properties.. **2022**,	1
147	Drug-likeness scoring based on unsupervised learning.. **2022**, 13, 554-565	0
146	to development of a polyherbal against .. **2022**, 8, e08789	
145	Recent advancement in drug development of nitro(NO)-heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis.. **2022**,	0
144	Synthesis of tropane-based receptor antagonists with antiallodynic activity.. **2022**, 230, 114113	1
143	Optimization of physicochemical properties is a strategy to improve drug-likeness associated with activity: novel active and selective compounds against Trypanosoma cruzi.. **2022**, 171, 106114	0
142	Regioselective synthesis, physicochemical properties and anticancer activity of 2-aminomethylated estrone derivatives.. **2022**, 219, 106064	0
141	Discovery of HDAC6-Selective Inhibitor NN-390 with Efficacy in Group 3 Medulloblastoma.. **2022**,	4
140	Selected Applications of Spirocycles in Medicinal Chemistry. **2022**, 9-34	

139	Machine learning & deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry.. **2021**,	0
138	Efficient and selective hydrogenation of quinolines over FeNiCu/MCM-41 catalyst at low temperature: Synergism of Fe-Ni and Ni-Cu alloys. **2022**, 520, 112166	0
137	Fragment-to-Lead Medicinal Chemistry Publications in 2020.. **2021**,	7
136	Armeniaspirol analogues with more potent Gram-positive antibiotic activity show enhanced inhibition of the ATP-dependent proteases ClpXP and ClpYQ.	0
135	Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors.. **2022**,	1
134	Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore.. **2022**,	1
133	Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes.. **2022**,	0
132	Association of Dietary Intake of Polyphenols with an Adequate Nutritional Profile in Postpartum Women from Argentina.. **2022**, 27, 20-36	1
131	Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe.. **2022**, 65, 4972-4990	0
130	Combined Machine Learning and GRID-Independent Molecular Descriptor (GRIND) Models to Probe the Activity Profiles of 5-Lipoxygenase Activating Protein Inhibitors.. **2022**, 13, 825741	1
129	Covalent Proximity Scanning of a Distal Cysteine to Target PI3K **2022**,	4
128	In Silico Approaches for Some Sulfa Drugs as Eco-Friendly Corrosion Inhibitors of Iron in Aqueous Medium. **2022**, 10, 43	0
127	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.. **2022**, 178, 106156	2
126	An efficient drug compound analysis using spectral deep feature classification based compound analyse model for drug recommendation. **2022**, 2, 100059	
125	Bioactivity and Biotechnological Overview of Naturally Occurring Compounds from the Dinoflagellate Family Symbiodiniaceae: A Systematic Review.. **2021**, 2021, 1983589	0
124	Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).. **2022**, 13, 84-91	2
123	Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity. **2021**,	9
122	In Silico Design and Molecular Docking Studies of Carbapenem Analogues Targeting Acinetobacter baumannii PBP1A Receptor. **2022**, 20, 35-50	0

121	Uncovering a Hub Signaling Pathway of Antimicrobial-Antifungal-Anticancer Peptides' Axis on Short Cationic Peptides via Network Pharmacology Study.. **2022**, 23,	0
120	One-Pot Synthesis of 1,8-Dioxodecahydroacridines Catalyzed by Carbon-Doped MoO3. **2022**, 58, 394-404	
119	Cobalt-Catalyzed Carbonylation for the Synthesis of N-Heterocyclic Compounds. **2022**, 357-379	
118	The -Trisubstituted Hydroxylamine Isostere and Its Influence on Lipophilicity and Related Parameters.. **2022**, 13, 799-806	0
117	Discovery of benzo[d]oxazol-2(3H)-one derivatives as a new class of TNIK inhibitors for the treatment of colorectal cancer.. **2022**, 67, 128745	0
116	Data_Sheet_1.PDF. **2018**,	
115	Data_Sheet_1.PDF. **2020**,	
114	Data_Sheet_1.CSV. **2018**,	
113	Data_Sheet_2.docx. **2018**,	
112	Table_1.XLSX. **2018**,	
111	Table_2.XLSX. **2018**,	
110	Table_1.PDF. **2018**,	
109	Table_2.PDF. **2018**,	
108	Table_3.PDF. **2018**,	
107	Table_4.pdf. **2018**,	
106	Table_5.pdf. **2018**,	
105	Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit.. **2022**,	2
104	Screening the efficacy of cannabinoids on neurodegeneration mediated by ER stress and Cannabinoid Receptors. **2022**,	

103	One-Pot Synthesis of Novel Hydrazono 1,3-Thiazolidin-4-One Derivatives: Molecular Modelling, ADMET And Biological Evaluation of Anti-HIV And Anti-Tubercular Agents.. **2022**,	
102	Electrostatic Complementarity in Structure-Based Drug Design.. **2022**,	2
101	Carboxylic Acid Bioisosteres in Medicinal Chemistry: Synthesis and Properties. **2022**, 2022, 1-21	1
100	Copper-Catalyzed Electrophilic Arylation of Isatoic Anhydride with Diaryliodonium Salts for Synthesis of N-Phenylated Isatoic Anhydrides.	1
99	Discovery of benzamide derivatives containing urea moiety as soluble epoxide hydrolase inhibitors. **2022**, 105898	0
98	Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification. 13,	0
97	Design and synthesis of chromone-based monoamine oxidase B inhibitors with improved drug-like properties. **2022**, 114507	
96	Economical, efficient, and environmentally friendly synthesis strategy of O-Alkylation strategy based on phenolphthalein reactions with electrophiles: Characterization, DFT study, and molecular docking. **2022**, 1265, 133424	0
95	Synthesis of symmetrical secondary oligoethylene glycolated amines from diethanolamine.	
94	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. **2022**, 15, 747	0
93	Studying Lipophilicity Trends of Phosphorus Compounds by 31P-NMR Spectroscopy: A Powerful Tool for the Design of P-Containing Drugs. **2022**, 65, 8511-8524	0
92	Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and butyrylcholinesterase. **2022**, 12, 19764-19855	6
91	Discovery of Pyridyl Urea Sulfonamide Inhibitors of NaV1.7. **2022**, 128892	
90	Palladium-Catalyzed Dual Catalytic Synthesis of Heterocycles.	
89	Photocontrollable Fluorescence Imaging of Mitochondrial Peroxynitrite during Ferroptosis with High Fidelity. **2022**, 94, 10213-10220	1
88	Insilico validation and comparison of antifungal competence and druglikeness of some natural xanthones A step towards antimycotic therapeutics. **2022**, 99, 100577	
87	Iron-catalyzed synthesis of N-heterocycles via intermolecular and intramolecular cyclization reactions: A review. **2022**, 15, 104095	
86	Pharmacological significance of nitrogen-containing five and six-membered heterocyclic scaffolds as potent cholinesterase inhibitors for drug discovery. **2022**, 120, 250-259	4

85	New s-Triazine/Tetrazole conjugates as potent antifungal and antibacterial agents: Design, molecular docking and mechanistic study. **2022**, 1267, 133615	3
84	Recent progress in organophotoredox reaction.	2
83	Drug approval prediction based on the discrepancy between gene perturbation effects in cells and humans.	
82	Liquid Chromatography on the Different Methods for the Determination of Lipophilicity: An Essential Analytical Tool in Medicinal Chemistry. **2022**, 10, 340	2
81	Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.	0
80	Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. **2022**, 183, 106362	0
79	Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. **2022**, 12,	1
78	Polypharmacology in Drug Design and Discovery Basis for Rational Design of Multitarget Drugs. **2022**, 397-533	0
77	Quinoline hydrazone hybrids as dual mutant EGFR inhibitors with promising metallic nanoparticle loading: rationalized design, synthesis, biological investigation and computational studies. **2022**, 46, 18207-18232	1
76	Fragment optimization and elaboration strategies the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.	0
75	On drug discovery against infectious diseases and academic medicinal chemistry contributions. 18, 1355-1378	0
74	Virtual screening of flavonoids from Chamaecrista genus: ADME and pharmacokinetic properties, interactions of flavonoid DNA complex by molecular docking and molecular dynamics. 1-9	0
73	Molecular fingerprints are not useful in large-scale search for similarly active compounds	0
72	Facile synthesis, crystal structure, biological evaluation, and molecular modeling studies of N-((4-acetyl phenyl) carbamothioyl) pivalamide as the multitarget-directed ligand. 10,	0
71	Ethyl 5-Oxo-5-(((12-oxoindolo[2,1-b]quinazolin-6(12H)-ylidene)amino)oxy)pentanoate. **2022**, 2022, M1451	0
70	In Silico Positional Analogue Scanning with Amber GPU-TI. **2022**, 62, 4448-4459	1
69	Scaffold and structural diversity of the secondary metabolite space of medicinal fungi.	0
68	Molecular iodine-promoted oxidative cyclization for the synthesis of 1,3,4-thiadiazole-fused-[1,2,4]-thiadiazole incorporating 1,4-benzodioxine moiety as potent inhibitors of amylase and glucosidase: In vitro and in silico study. 10,	3

67	The development of small-molecule inhibitors targeting HPK1. **2022**, 244, 114819	0
66	In-silico investigations on the anticancer activity of selected 2-aryloxazoline derivatives against breast cancer. 1-10	0
65	Carboxylate-Capped Analogues of Ru265 Are MCU Inhibitor Prodrugs. **2022**, 61, 17299-17312	0
64	Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes. **2022**, 114883	0
63	Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox.	0
62	Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug-Able Anti-TB Phytochemicals: A Cost-Effective Platform for Natural Product-Based Drug Discovery.	0
61	The Time and Place for Nature in Drug Discovery.	3
60	Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema. **2022**, 65, 13629-13644	0
59	Vasodilation of Pre-contracted Porcine Retinal Arteries by Carbonic Anhydrase Inhibitors with Enhanced Lipophilicity. **2022**, 47, 1615-1621	0
58	Therapeutic potential for P2Y2 receptor antagonism.	0
57	From dopamine 4 to sigma 1: Synthesis, SAR and biological characterization of a piperidine scaffold of 1 modulators. **2022**, 244, 114840	0
56	Molecular Dynamics Simulations of Self-Assembling Colloids in Fed-State Human Intestinal Fluids and Their Solubilization of Lipophilic Drugs.	1
55	Properties of FDA-approved Small Molecule Protein Kinase Inhibitors: A 2023 Update. **2022**, 106552	6
54	Delivering on the promise of recombinant silk-inspired proteins for drug delivery. **2022**, 114622	1
53	Insights into the equilibrium structure and translocation mechanism of TP1, a spontaneous membrane-translocating peptide. **2022**, 12,	0
52	Design, and synthesis of selectively anticancer 4-cyanophenyl substituted thiazol-2-ylhydrazones. **2022**, 12, 34126-34141	0
51	Application space for SFC in pharmaceutical drug discovery and development. **2022**, 29-47	0
50	NPASS database update 2023: quantitative natural product activity and species source database for biomedical research.	0

49	Synthetic Imidazopyridine-Based Derivatives as Potential Inhibitors against Multi-Drug Resistant Bacterial Infections: A Review. **2022**, 11, 1680	0
48	Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity. **2022**, 14, 2703	0
47	The Identification of Potent, Selective, and Brain Penetrant PI5P4K□Inhibitors as In Vivo-Ready Tool Molecules.	2
46	Machine learning-based prediction of drug approvals using molecular, physicochemical, clinical trial, and patent-related features. 1-17	0
45	Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3K□**2022**, 65, 16589-16621	2
44	Formation of nitrogen-containing six-membered heterocycles on steroidal ring system: A review. **2022**, 109171	2
43	Synthesis of Benzothiazole Linked Triazole Conjugates and Their Evaluation Against Cholinesterase Enzymes. **2022**, 7,	0
42	Scaffold and Structural Diversity of the Secondary Metabolite Space of Medicinal Fungi.	0
41	Integration of Synthetic Organic Chemistry and <i>in silico</i> Drug Discovery - Lead Discovery of Renin Inhibitors and <i>O</i>-GlcNAcase Inhibitors. **2023**, 81, 25-34	0
40	Fragment-to-Lead Medicinal Chemistry Publications in 2021.	0
39	Stereoselective Synthesis and Antiproliferative Activities of Tetrafunctional Diterpene Steviol Derivatives. **2023**, 24, 1121	0
38	Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter. **2023**, 66, 371-383	0
37	Screening potential ligands of endothelin receptor A from Choerospondias axillaris and evaluation of their drug-like properties by affinity chromatographic methods. **2023**, 226, 115240	0
36	Palladium-catalyzed C-N Coupling Reactions in the Synthesis of Dibenzodiazepines. **2022**, 26, 1813-1826	0
35	Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach. **2023**, 13, 162	0
34	Drug Discovery in Real Life: An Online Learning Activity for Bioinformatics Students.	0
33	Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens. **2023**, 12, 274	2
32	Recent Advances in N-Heterocyclic Small Molecules for Synthesis and Application in Direct Fluorescence Cell Imaging. **2023**, 28, 733	0

31	The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro, and in silico mechanistic investigations. 1-15	2
30	Computational phytochemistry, databases, and tools. **2023**, 39-55	0
29	Druggable sites identification in Streptococcus mutans VicRK system evaluated by catechols. 1-16	0
28	Drug discovery: Standing on the shoulders of giants. **2023**, 207-338	0
27	Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.	0
26	Current and emerging approaches to noncompetitive AR inhibition.	0
25	Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective. **2023**, 11, 469	0
24	Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. **2023**, 66, 2904-2917	0
23	Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection. **2023**, 66, 2347-2360	0
22	Screening for bilayer-active and likely cytotoxic molecules reveals bilayer-mediated regulation of cell function. **2023**, 155,	0
21	Dockey: a modern integrated tool for large-scale molecular docking and virtual screening. **2023**, 24,	1
20	Cheminformatics Bioprospection of Sunflower Seeds Oils against Quorum Sensing System of Pseudomonas aeruginosa. **2023**, 12, 504	0
19	A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy. **2023**, 15, 913	0
18	The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders. **2023**, 14, 499-505	0
17	Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents. **2023**, 12, 744	0
16	Medicinal chemistry strategies in the discovery and optimization of HBV core protein allosteric modulators (2018–2022 update). **2023**, 108349	0
15	Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface. **2023**, 15, 1822	0
14	Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology. **2023**, 24, 5819	0

13	Synthesis and Evaluation of some Novel Triazolo-thiadizoles Derivatives as Anti-diabetic Activity. **2023**, 1-7	0
12	Conformationally Restricted Receptor Antagonists from (Isopulegol. **2023**, 66, 4999-5020	0
11	Drug discovery and development. **2023**, 35-41	0
10	Applications of Bioisosteres in the Design of Biologically Active Compounds.	0
9	Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors. **2023**, 24, 6298	1
8	A combined in silico approaches of 2D-QSAR, molecular docking, molecular dynamics and ADMET prediction of anti-cancer inhibitor activity for actinonin derivatives. 1-15	0
7	CDGCN: Conditional de novo Drug Generative Model Using Graph Convolution Networks. **2023**, 104-119	0
6	Magic Chloro Profound Effects of the Chlorine Atom in Drug Discovery.	0
5	meta-Selective O-Arylation of Cyclic Diaryliodonium Salts with Phenols via Aryne Intermediates.	0
4	Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. **2023**, 106774	0
3	Synthetic Access to Bis(pyrazolyl)methanes using cost-efficient Triethylammonium Hydrogen Sulfate Ionic Liquid: Evaluation of Antioxidant Activity via in silico and in vitro Studies. **2023**, 8,	0
2	Integration of Chemoinformatics and Multi-Omics Analysis Defines ECT2 as a Potential Target for Cancer Drug Therapy. **2023**, 12, 613	0
1	Accelerating therapeutic protein design with computational approaches toward the clinical stage. **2023**, 21, 2909-2926	0